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ABSTRACT
Hypoplastic Left Heart Syndrome (HLHS) is a congenital heart disease where the left
ventricle and ascending aorta are underdeveloped. The first of three palliative surgeries
for this malformation is the Norwood procedure. In this surgery, an opening is made
between the left and right atrium so that all blood can flow into the right ventricle (RV).
A reconstructed aorta is anastomosed (connected) to the RV so that the RV can pump
oxygenated blood to the body (the systemic circulation). To divert part of the systemic
blood flow to the pulmonary circulation, the modified Blalock-Taussig Shunt (mBTS) is
connected from the innominate artery to the pulmonary artery. However, Norwood
patients with an mBTS may experience retrograde flow from the coronary circulation
(which supplies blood to the heart) to the pulmonary circulation via the mBTS. This
shunt steal of coronary blood can lead to detrimental issues such as myocardial ischemia
leading to right ventricular dysfunction.
In this study, a multi-scale model of the Norwood procedure couples a threedimensional (3D) test section of the reconstructed aortic arch with a lumped parameter
network (LPN) describing the Norwood patient’s global hemodynamics. Previously, only
in silico multi-scale models of the Norwood circulation have modeled the coronary
circulation and the effects of varying mBTS sizes on coronary perfusion. Here, a novel in
vitro coronary circulation model is adapted from such in silico studies and implemented
into a previously validated in vitro mock circulatory system (MCS) of the Norwood with
mBTS palliation. The MCS was verified against an analytical model and validated using
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a patient-specific test section and data. A parametric test in which the size of the mBTS
inner diameter was varied from 3mm to 4mm was performed. The results showed that
increasing mBTS size results in decreased diastolic aortic pressure, which decreases
coronary blood flow (CBF) during diastole.
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CHAPTER ONE
THE NORWOOD PROCEDURE AND CORONARY CIRCULATION
Hypoplastic Left Heart Syndrome
Every year there are approximately 10 in 10,000 children born with Hypoplastic Left
Heart Syndrome [1]. Although rare, this congenital disease is one of the deadliest and
attributes to 20% of the heart-related deaths in newborns per year [1]. The HLHS
physiology is marked by a severely underdeveloped left ventricle (LV) and aorta that are
unable to support the systemic circulation: the blood flow that provides oxygen to the
body. Other characteristics of this disease may include aortic valve or mitral valve
stenosis [2]: narrowing that further hinders the blood flow through the left side of the
heart. A full anatomical representation of the HLHS heart relative to a normal healthy
heart can be seen in Figure 1.1.

Figure 1.1 Anatomy of a normal heart (Left) and a heart with HLHS (Right). [3]
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As seen in Figure 1.1, the hypoplastic LV’s size greatly limits its ability to
provide oxygenated blood to the systemic circulation. At birth, the patent ductus
arteriosus (PDA) connects the pulmonary artery to the aortic arch, providing oxygenated
blood to the systemic circulation. However, the PDA will close within a few weeks after
birth and, unless medically intervened, the disease is fatal [4]. Symptoms of HLHS
include fatigue or cyanosis: where the patient’s skin tone appears blue, a mark of oxygen
insufficiency [4]. This alerts doctors to perform medical imaging techniques such as
echocardiography, and from there HLHS can be diagnosed. Once diagnosed,
reconstruction of the heart is performed within 2-5 days of the patient’s life. [4]
HLHS patients are treated with a set of 3 palliative surgeries: the Norwood,
Glenn, and Fontan. The Norwood procedure (Stage 1) and its many variations occur
within the first few days of birth. The Glenn procedure (Stage 2) occurs within 4-6
months. The previous surgeries are all performed with the end goal to create the Fontan
circulation, marked by the total cavo-pulmonary connection [5]. This is the Fontan
procedure (Stage 3) and occurs when the patient is 2-6 years old [4]. Overall, the survival
rate to adulthood for these patients is limited, particularly with 5-30% mortality after
Stage 1 [4, 6]. Due to these high rates, the Norwood procedure continues to be a topic of
research in hopes of discovering new methods or optimizing the current palliative
method.
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Stage 1 Anatomy and Physiology
The purpose of the Norwood procedure is to provide both systemic and
pulmonary blood flow [7]. To do this, a neo-aorta is constructed using the hypoplastic
ascending aorta and a homograft patch, and anastomosed (connected) to the pulmonary
trunk. The native aortic trunk may then be anastomosed to the neo-aorta by means of the
Damus-Kaye-Stansel (DKS) procedure. In this configuration, the RV now acts as the
systemic ventricle and pumps blood into the neo-aorta to the systemic circulations: upper
body, lower body, and coronary circulations. The RV receives both oxygenated and
deoxygenated blood from the right atrium (RA) and the left atrium (LA) via the atrial
septal defect: an opening between the RA and LA.
The trademark of Stage 1 is the means by which it diverts part of the blood flow
back to the pulmonary arteries (PA) to be oxygenated in the lungs. This is achieved using
a shunt such as the modified Blalock-Taussig shunt (mBTS). Figure 1.2 shows the Stage
1 with mBTS palliation of a HLHS heart.

Figure 1.2 Anatomy of the Stage 1 with mBTS palliation for HLHS. [3]
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The mBTS is a polytetrafluorethylene conduit from the innominate artery
(INOM) or subclavian artery to the left or right PA [6]. When blood is pumped from the
RV, it travels up through the aorta into the systemic arteries, including the INOM. As
blood passes through the INOM, it can then pass through the mBTS to the PA. This
completes the parallel systemic and pulmonary circulation [7] of the Norwood
physiology, which is in contrast to a series circulation for a normal patient.
From Figure 1.2, it can be seen that the RV is the main pumping mechanism for
the Norwood heart. It provides the flow of blood into the ascending aorta, the cardiac
output (CO), which is used to perfuse both the systemic and pulmonary circulations. As
indicated by Figure 1.2, the CO is mixed with both oxygen-rich and oxygen-poor blood.
Placement and size of the mBTS is chosen in order to provide a proper balance of
pulmonary-to-systemic blood flow (QP/QS) [8]. This is necessary to ensure that correct
blood-oxygen saturation rates are met.
The mBTS’s performance is highly dependent on the pulmonary vascular
resistance (PVR), which is much smaller relative to the systemic vascular resistance
(SVR), and changes with patient growth [9]. In vitro studies have found that a ratio of
about 1:1 for Qp/QS using a mBTS with a diameter of 3.5 mm is optimal for systemic
oxygenation [8-9]. While achieving this balance is possible, the mBTS is still marked by
complications. Most notably, the mBTS has been associated with “shunt steal”: diastolic
flow into the mBTS from retrograde flow in the systemic arteries [10]. In particular, this
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diastolic runoff into the pulmonary circulation has been associated with detriment to the
flow of blood in the coronary circulation. [6, 10–12]
Coronary Arteries for the Healthy Heart
The heart can be thought of as a pump whose energy source is oxygenated blood
traveling through the coronary circulation. In a healthy heart, the coronary circulation is
composed of coronary arteries that originate at the two ostia located in the aortic sinuses
behind the aortic valve, as seen in Figure 1.3 below. From there, the left (LCA) and right
(RCA) coronary arteries spread over the outer epicardium and descend into the inner
myocardium and innermost endocardium of the left and right ventricles, respectively.
This blood flow provides the oxygen the heart muscle needs for contraction during
systole. The deoxygenated blood is then directed through coronary veins that empty into
the RA. [13]

Figure 1.3 Anatomy of a normal heart detailing the location of the coronary arteries. [14]
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Total coronary blood flow (QCOR or CBF) is said to be about 4% of the CO and
predominantly occurs during diastole [15]. This time dependent flow is related to the
interaction of the systemic ventricle and myocardium with the coronary vessels [13].
During systole, the ventricle contracts and increases the intramyocardial tissue pressure
[16], squeezing the coronary vessels and increasing their resistance to arterial coronary
blood flow (CBF). Additionally, the forward-moving cardiac output opens the aortic
valve and the valve leaflets form a barrier between the coronary ostia and the flow
(Figure 1.4).

Figure 1.4 The aortic valve leaflet position during (A) systole and (B) diastole. Arrows show
blood flow direction [17].

As seen in Figure 1.4, it is during diastole that the aortic sinuses fill and the coronary
arteries receive blood. When the aortic valve closes, it is the start of ventricular
isovolumetric relaxation and diastole. Here the coronary vessels are least subjected to the
intramyocardial pressure from ventricular movement and have the greatest coronary
perfusion pressure (CPP): the difference between diastolic aortic pressure and atrial
pressure. And so, this is where CBF is at its maximum [18]. Then as the diastolic aortic
pressure decreases through the end of the cardiac cycle, the CPP decreases and CBF
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responds similarly. This agrees with the echocardiograms (echos) of coronary flow
velocities seen in Figure 1.5, where the majority of flow is during diastole.

Figure 1.5 Echos of coronary flow of the left anterior descending coronary artery for a (Left)
post-aortic-valve replacement patient [19] and (Right) a normal heart [20]. S and D represent systole
and diastole, respectively.

In Figure 1.5, the differences between flow in systole versus diastole are quite distinct
for both images. The image on the left is from the Left Anterior Descending artery for a
patient who had undergone aortic valve replacement surgery, while the image on the right
is from the same artery of a healthy human’s heart. It is apparent that the heart receives
blood, and thus oxygen, during its relaxed stage of diastole – the supply. It is also clear
that during systole, when the heart is exerting itself and in need of energy, it is not
receiving as much flow – the demand. This supply-demand relationship can be further
understood by the Myocardial Oxygen Supply-Demand Balance (MOB) [18].
The MOB dictates the coronary vasomotor tone’s response. This results in
vasodilation or vasoconstriction of the coronary vessels to allow for increased or
decreased CBF, respectively [21]. The MOB relates the ratio of the amount of CBF the
heart needs versus the amount of CBF supplied. Factors affecting the supply of oxygen to
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the heart include heart rate (HR), CPP, blood oxygen content, and the diameter of the
coronary artery [18]. The demand of oxygen is also governed by HR, preload and
afterload on the ventricle, and myocardial inotropy [18]. Thus, the more forcefully and
longer the ventricle must contract in systole, the more it will demand oxygen. Likewise,
the longer the ventricle is relaxed in diastole or the more pronounced the diastolic aortic
pressure, the greater the supply of oxygen to the myocardium. A quantitative
measurement of the MOB is made through the Endocardial Viability Ratio (EVR) [21].
The EVR is the ratio of the Diastolic Pressure Time Index (DPTI) to the Tension
Time Index (TTI) [21]. The DPTI is the “product of the coronary perfusion pressure and
diastolic time,” while the TTI is the “product of systolic pressure and systolic time” [21].
In healthy circumstances, the EVR value is 1 or greater, meaning that the oxygen supply
meets or exceeds the demand. However, an EVR below 0.7 typically signifies ischaemic
conditions [21], meaning the heart tissue is not properly oxygenated for the amount of
work it is performing. In these conditions, the blood flow to the coronary circulation is
being obstructed. It is important to note that the rate of myocardial oxygen extraction
does not increase as substantially as myocardial oxygen demand [16]. Furthermore, an
increase in oxygen supply to overcome a low EVR can only be met by an increase in
CBF [15]. And so, any deterrent of coronary blood flow will be to the detriment of the
heart. Unfortunately, such a deterrent exists in the Stage 1 physiology.
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Coronary Arteries in Norwood Physiology
During Stage 1 procedure, some surgeons prefer to not transplant the fragile coronary
arteries to the neo-aorta [22]. Instead, as mentioned above, they perform the DKS
procedure [23]. In this method, the native aortic root is anastomosed to the neo-aorta,
allowing for blood flow from the RV up through the neo-aorta to descend into the native
aorta and perfuse the coronaries. In this configuration, the coronary arteries are allowed
to maintain their native origin.
Studies have shown that the size of the coronary arteries and ostia between HLHS
patients and those of normal conditions do not differ [24]. However, according to
Donnelly et al, Norwood patients are said to have “less [coronary] perfusion and oxygen
delivery to the systemic ventricle” [12]. Donnelly further mentioned that the hypoplastic
LV might even steal from the RV, which is performing an additional workload as it
supports both systemic and pulmonary circulations.
In an in vivo study of patients after the Norwood surgery, Charpie et al. found that
patients requiring medical intervention for decreased ventricular function correlated with
having higher QP/QS ratios and less systemic oxygen delivery than patients who did not
need medical intervention [25]. The choice of mBTS, particularly its size, is used to
control the QP/QS ratio. These results reveal the sensitivity that myocardial function has
to the mBTS. These findings have been further expressed in other studies that say, when
compared to other Stage 1 shunting options, the mBTS has the more devastating effects
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on coronary perfusion [8, 10, 11]. These particular effects of the mBTS are referred to as
“shunt steal” of the coronary blood flow [10].
Shunt steal of the CBF occurs when the mBTS, which is an open channel throughout
the cardiac cycle, “steals” blood that would typically flow towards the coronary
circulation. The diastolic aortic pressure, which would normally help perfuse the
coronaries, instead directs the flow towards the pulmonary circulation, which has less
resistance than the coronary arteries. The end result is that the coronary arteries do not
receive as much blood as they typically would. For a single ventricle performing
increased workload, the combination of decreased blood supply (which means decreased
oxygen supply) and the potential for the hypoplastic ventricle to steal what blood does go
to the coronary circulation, the mBTS presents unfavorable odds for ventricular health.
Arguments have been made in favor of other Stage 1 procedures. These would
eliminate the mBTS by shunting to the pulmonary circulation using a different method,
thus removing the shunt steal’s effect on coronary perfusion [2, 6]. For instance, the
Right Ventricle – Pulmonary Artery (RVPA) shunt is said to provide better
hemodynamics, less shunt steal, and improves overall survival rate to the 2nd surgery [2],
[26]. However, the invasiveness of anatomically altering the only healthy ventricle is of
concern for some medical professionals. Thus, it is still useful to research improvements
to and develop better understanding of the Stage 1 with mBTS. This research can be
performed using multi-scale modeling methods.
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Multi-scale Modeling of the Norwood with mBTS
In multi-scale modeling, a 3D model is coupled to a zero-dimensional (0-D) LPN,
which provides the model’s inlet and outlet boundary conditions [27]. In terms of HLHS,
multi-scale modeling has been used to model the Norwood palliation for both general and
patient specific cases to study the hemodynamics that cannot be captured in vivo [28].
These models incorporate a 3D model of interest (i.e. aortic arch) of the HLHS patient
that captures the local hemodynamics of the system. The 0-D LPN governs the model’s
inlet and outlet boundary conditions. The LPN provides the system-level pressures and
blood flow rates of the entire “circulatory network” through its use of resistance (R),
inertance (L), and capacitance (compliance) (C) elements to create an impedance of each
circulation [27]. Migliavacca et al. explained that the reasoning for integrating the LPN to
a 3D model is that “the whole circulatory network [of the Norwood palliation] has to be
taken into account for the evaluation of the hemodynamics in the specific region [3D
model].” [27]
The multi-scale models for the Norwood hemodynamics have been accomplished
using experimental (in vitro) mock circulatory systems and computational or numerical
(in silico) models. As described by Biglino et al., some of the key advantages of these
models include their ability to acquire detailed information of the hemodynamics that
cannot be captured clinically (in vivo), be a tool for educational purposes and medical
device testing, and provide “what-if” scenarios for parametric studies of varying surgical
options [29]. In the following studies, the aortic arch of a Norwood patient was coupled
to a LPN composed of impedances that represent the upper body, lower body, pulmonary,
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and coronary circulations. The first of these is an in silico study by Migliavacca et al.
who looked into the effects of the various shunt options for the Stage 1 surgery.
Schematics of their models are seen in Figure 1.6.

Figure 1.6 In silico multi-scale models of the Norwood with RVPA (Left) and mBTS (Right) [27]

In this study, Migliavacca et al. found that the choice of shunt had a large effect on
the relationship between pulmonary flow and coronary perfusion. The RVPA shunt,
when compared to mBTS, had the greatest CBF because it allowed for a higher diastolic
aortic pressure [27], and thus greater CPP. However, the central shunt (CS), which
connects from the ascending aorta to PA to provide for systemic to pulmonary flow,
lowered the coronary perfusion pressure and flow. It also had more pulmonary flow than
the mBTS. This shows the relationship between the systemic-pulmonary shunt’s
placement and coronary perfusion. It appears that shunts placed in closer proximity to the
ascending aorta result in more pulmonary flow and less CBF.
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In an in silico study that only looked at the mBTS, focus was given to the effects
caused by placement and size (inner diameter) of the shunt. Here, Moghadam et al. found
that the shunt diameter had a greater effect on coronary oxygen delivery than did the
placement (proximal or distal) along the innominate artery [9]. Specifically, a smaller
shunt increased the aortic pressure, which allowed for more coronary flow due to a higher
CPP. A shunt placed distal along the innominate artery also allowed for optimal coronary
oxygen delivery, whereas a proximal placement optimized non-coronary systemic oxygen
delivery. For a combined optimization of systemic and coronary oxygen delivery,
Moghadam et al. found that a shunt placed between the distal and proximal location with
a 3.41 mm diameter was most efficient [9]. These results agreed with Migliavacca et al.’s
findings that mBTS size affects the PVR in such a way that blood in the aortic arch
during diastole is stolen from the coronaries.
Lagana et al. also looked at the effects of the mBTS compared to the CS with their
computational multi-scale model. In this study, the results agreed with Moghadam et al.:
the mBTS was better than the CS for coronary perfusion, but increasing mBTS diameter
did increase pulmonary flow at the loss of coronary. Further, Lagana et al. found that
coronary flow made up 2.98% to 3.83% of the cardiac output when using the mBTS, and
that halving the coronary resistance greatly increased the coronary perfusion. This
indicates that coronary resistance is a major contributor to determining CBF. Overall, the
mBTS was recommended over the CS as the Stage 1 shunt option [11].
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In a study focused solely on the mBTS, Corsini et al. used their in silico model to see
how coarctation (COA), a localized narrowing of the aorta, and mBTS size affected
coronary perfusion. A large shunt with severe COA was found to be unfavorable for the
coronary perfusion and oxygen delivery. The severe COA caused an increase in the
afterload, and resulted in decreased cardiac output. The idea of shunt steal was supported
as increased COA severity resulted in an increase QP/QS and decreased coronary flow.
When maintaining constant cerebral perfusion, similar results were obtained [10].
Overall, these in silico models come to the same conclusion: the mBTS provides
better hemodynamics than the CS, while underperforming compared to the RVPA. When
looking only at the mBTS, larger shunt options decreased the diastolic aortic pressure,
and so decreased CPP and coronary oxygen delivery. COA in the presence of the mBTS
further hinders the coronary performance. These results were performed exclusively
using computational methods and rely on the methods chosen to solve the local fluid
dynamics of the 3D model – a risk in using in silico models. Therefore, the in vitro
models are useful in their ability to reliably provide the local hemodynamics of the 3D
model being studied. Together, the in vitro models can be used to verify the results
obtained from in silico models. Unfortunately, an in vitro model of the Norwood
palliation that includes the coronary circulation does not exist.
Prior to the work detailed in this thesis, Hang’s in vitro model for the Stage 1
palliation was limited to providing details about the pulmonary, upper body, and lower
body circulations [28]. In his research, Hang validated his MCS against patient-specific
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parameters obtained clinically. He then investigated the effects of COA on both the
mBTS and RVPA Norwood palliations by introducing a range of COA severities to the
model. Five patient-specific 3D models were used in his study to further investigate the
effects of morphology. His findings showed that the RVPA does improve the QP/QS
when compared to the mBTS. He also showed that severe COA resulted in more drastic
changes to QP/QS, and that atypical aortic arch morphology was associated with larger
ventricle power [28].
In terms of the results on pulmonary to systemic flow, Hang’s results agree with those
found by the aforementioned in silico models. However, the in vitro model did not
include the coronary circulation. As shown above, coronary perfusion and oxygen
delivery are heavily dependent on modifications that affect QP/QS. This leads to the
objectives of the present study.
Research Objectives and Hypothesis
The following are the objectives of this study:
1. Design and integrate a coronary circulation into a previously validated in vitro
multi-scale model [28]
2. Verify the system’s response against a mathematical (analytical) model
3. Validate the in vitro coronary blood flow against clinical findings in literature
4. Validate the entire in vitro model against clinical data of a HLHS patient
5. Investigate the effects of mBTS size on coronary perfusion
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Additionally, the following is hypothesized:
6. The in vitro model will illustrate how increased mBTS size negatively affects
coronary perfusion
The hypothesis will be accepted in the case where increased shunt size results in
decreased coronary blood flow and a connection between the two can be proven. The
hypothesis will be rejected in the case where there is no discernable drop in coronary
blood flow with increasing shunt size.
In completing these objectives, the in vitro model will allow experimentation of the
Norwood hemodynamics and morphology with respect to coronary perfusion. In
particular, assessing the mBTS’s effect will allow detection of whether or not shunt steal
of coronary perfusion exists. No experimental findings have been recorded for this
phenomenon and doing so would either verify or negate in silico results. In the next
chapters, focus will be given to the methods taken to create this system, in particular to
the coronary circulation.
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CHAPTER TWO
IN VITRO CORONARY CIRCULATION MODELING
Early Coronary Blood Flow Models
A major complication of CBF is its interaction with myocardial contraction and
relaxation. The upper body, lower body, and pulmonary circulations in in vitro LPNs
have static impedances whose blood flow and pressure are strictly governed by the fixed
impedance values, the upstream aortic pressure, and downstream atrium pressure [28].
This is unlike the coronary circulation, whose impedance must account for myocardial
contraction through a dynamic response. This complication was initially addressed by
Downey and Kirk’s waterfall model [30] and then improved on by Spaan et al.’s
intramyocardial pump (IMP) model [31] (Figure 2.1).

a)

b)
Figure 2.1 (a) Schematic of the waterfall model by Downey and Kirk [32]: (top) collapsible
tube with inflow pressure PA, outflow pressure PV, exterior pressure PT. (middle) flow graph
as a function of PA for two cases of PT. (bottom) electrical analogue of where VA is PA, VT is
PT, and current is flow. (b) Schematic of the intramyocardial pump model by Spaan et al.
[31]: intramyocardial tissue pressure Pim and capacitance Cim, arterial and venous coronary
resistances Ra and Rv, intramyocardial blood pressure Pib, perfusion pressure Pp, and left
coronary artery pressure Plc. Figures reprinted with permission of original authors.
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The waterfall model (Figure 2.1a) is a “time-varying resistance model” for CBF [31].
Downey and Kirk believed that intramyocardial tissue pressure increases in systole as a
result of the cardiac contraction. As the intramyocardial tissue pressure increases during
systole, the pressure difference between the tissue and within the coronary vessels results
in the vessels collapsing, thus increasing the vessels’ resistance [30, 32]. And by the
relation that flow is determined by pressure drop across resistance, the arterial pressure
drives the coronary flow over coronary resistance towards the venous pressure. The
variations in the flow are strictly determined by the variations in the coronary resistance,
which is governed by intramyocardial tissue pressure.
To simulate this idea, Downey and Kirk’s model (top of Figure 2.1a) is composed of
an arterial pressure (Pa) and venous pressure (Pv), whose difference drives the flow
through the coronary vessel (i.e., a tube). The outer pressure (PT) represents the
intramyocardial tissue pressure, which increases and decreases during systole and
diastole, respectively. When PT exceeds the pressure within the tube, the tube will
increasingly collapse, mimicking an increased coronary vessel resistance during
ventricular contraction of systole [32]. This method is able to capture phasic differences
in arterial coronary flow: zero-flow during systole when PT is high and increased flow in
diastole when PT is low. However, it does not account for the systolic flow reversal seen
in vivo or for the venous coronary flow which is predominately during systole [31, 33].
This led Spaan et al. to develop their IMP model.
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To account for accurate arterial and venous coronary flow, the IMP model built on
the ideas of the time-dependent diode (resistance) model of Downey and Kirk. For the
IMP model, Spaan et al. implemented a volume pumping mechanism by incorporating a
capacitor connected to a time-dependent pressure (Figure 2.1b) [31]. They reasoned that
in addition to varying resistances to account for autoregulation, coronary vessels also
have their own capacitance. When combined with the time-varying intramyocardial tissue
pressure, the capacitance of the vessels helps regulate the differences between arterial and
venous coronary blood flow through blood volume changes [31]. The volume changes
are then directed upstream or downstream depending on the resistance of the arterial and
venous coronary beds.
From the schematic in Figure 2.1b, the time-varying intramyocardial pressure (Pim) is
translated across the intramyocardial capacitor (Cim) to the “intramyocardial blood
compartment” pressure (Pib) [31]. This results in variations of the Pib pressure, resulting
in a higher pressure in systole relative to diastole. With this change in pressure there is
also a change in blood volume stored at the capacitor, Cim. The direction (flow) and
amount of the blood volume is then determined by the arterial and venous coronary
resistances (Ra and RV, respectively), and by the Pib pressure relative to its up and
downstream pressures.
In systole, arterial flow is low and may even be retrograde when Pib exceeds the
upstream pressure. Further, in systole, the venous coronary flow is driven forward across
the venous resistance (Rv) because of the high Pib, mimicking cardiac contraction
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squeezing venous blood out of the coronary circulation. In diastole, Pib is lower and is not
as influenced by Pim. This allows for flow across the arterial resistor to then be stored
within Cim. Therefore, as that arterial flow moves into the capacitor during diastole and
Pib is low, the venous flow is at its minimum. An illustration of this model’s arterial
coronary flow relative to the systemic LV pressure can be seen in Figure 2.2.

Figure 2.2 Results from the IMP model and reprinted with permission by Spaan et al. Top is left
ventricle pressure, middle is coronary artery pressure, and bottom is coronary artery flow. [31]

The waterfall and IMP models were both groundbreaking in their ability to create
physiological portrayals of coronary blood flow and pressure. Since these models were
proposed, both in silico and in vitro models have been attempted based on their ideas.
The following in vitro models are not specifically Norwood models, but were
investigated to ensure that the most accurate method was chosen for the Stage 1 MCS.
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In Vitro Coronary Blood Flow Models
In recent years, limited accounts of experimental modeling of coronary blood flow
have been attempted [34–37]. Their aims were to create a representative circulation that
could model varying physiological conditions. An early attempt was by Geven et al. who
created a model for an adult human under normal and hyperemic conditions. Their goal
was to help validate the then newly developed “clinical diagnostic techniques” that were
used to capture coronary flows and pressures [34]. The model can be seen in Figure 2.3.

a)

b)
Figure 2.3 Schematics of the (a) LPN coronary model and (b) in vitro setup by Geven et al. [34]

In this model, Geven et al. modeled three components of the cardiovascular system:
the systemic LV and aorta, the systemic circulation, and the coronary circulation. The LV
is a piston-cylinder mechanism composed of an incoming venous flow and outgoing
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arterial flow to provide the inlet condition to the aorta: the aortic pressure and flow
waveforms [34]. The determinant of these waveforms is the systemic circulation, which
is made of a single compliance and a proximal and distal resistance. As fluid moves
through the aorta, it is allowed to pass into the coronary circulation.
Referencing Figure 2.3a, the “coronary artery” component of this circulation is
modeled with “physiological dimensions and capacitance” using a polyurethane tube.
The arterial resistance, Rar, and all subsequent resistances (except Rma) are made using
“manually adjustable clamps”. Similar to the waterfall model by Downey and Kirk, a
change in myocardial resistance due to myocardial contraction is accounted for by the
qmyo and Rma components of Figure 2.3a. In Figure 2.3b, a collapsible tube is shown to
pass through the LV chamber so that the inner LV pressure can physically manipulate the
resistance of the collapsible tube at this point in the circulation [34]. The authors refer to
their work as mimicking Downey and Kirk, however the collapsible tube provides it’s
own compliance, which is similar to Spaan et al.’s IMP model. This is shown in Geven et
al.’s results (Figure 2.4 below) where retrograde systolic CBF is achieved.

Figure 2.4 Clinical (top) and in vitro (bottom) coronary artery flow for normal (left) and
hyperemic (right) conditions [34]
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The results of Geven et al.’s experiment for normal and hyperemic conditions show
distinct differences in systolic versus diastolic flow, while even accounting for retrograde
flow during systole. Further, the results qualitatively agree with the in vivo reference.
However, this model is limited in that it lumps the entire systemic circulation into one
impedance element, which does not allow for the individual effects on specific systemic
branches to be described. Additionally, while the coronary circulation appears accurate,
passing a tube through the LV chamber would present a problem with Hang’s in vitro
setup [28]. Hang used a ventricular assist device (VAD) to provide the aortic pressure
and flow waveforms, and this device’s structure would not allow for a coronary tube to
be passed through it. Therefore, Geven et al.’s exact method would not work for
implementation into Hang’s MCS.
Pantalos et al. developed a 0-D MCS for pediatric cardiovascular systems [35]. Their
bench-top model allowed for various setups to help test different medical instruments
such as an intraaortic balloon pump or VADs. Their system, seen in Figure 2.4,
comprises both the systemic and pulmonary circulations. The coronary circulation is one
single tube running through a “dynamic resistor” [35]. Unlike Geven et al. and Spaan et
al., it does not account for compliance of the coronaries. The coronary flow is strictly
controlled by the variation in the resistor. Additionally, this model does not account for
venous coronary flow, although whether or not this was important to their setup is
unknown.
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Figure 2.4 Schematic of the experimental pediatric cardiovascular model with the (1) dynamic
coronary flow resistor by Pantalos et al. [35]

Looking at the results of Pantalos et al.’s study, clinical validation of their system was
only given to ventricle pressure and aortic flow and pressure [35]. The coronary flow was
not validated against any in vivo measurements. Initially, the model was used in a normal
setup, like the one seen in Figure 2.4. Then they modified the system to model the
cardiovascular system’s response to different medical devices. The literature does not
reveal whether the dynamic resistor was able to accurately capture a physiological flow
in the coronary circulation, especially when the results reveal such variability between
setups (Figure 2.5). Thus, this approach for coronary modeling was discarded.

Figure 2.5 Coronary artery flow for (Left) normal, (Middle) LV failure, and (Right) intraaortic
balloon pump models [35]
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In the same year, Gaillard et al. reported their work on modeling the effects of
aortic valve stenosis on the coronary circulation [36]. The model (Figure 2.6) is very
similar to that presented by Geven et al [34]. The system is composed of three branches:
the ventricle, systemic “aortic flow model”, and the coronary circulation. The coronary
circulation differs from Geven et al.’s in that it does not pass a collapsible tube through
the ventricle’s chamber. Instead, a tube is connected from that chamber and is passed to
another chamber. The resistor RLV is used to adjust the LV chamber pressure felt in the
“Sim” chamber [36]. This chamber has a collapsible tube passing through it so that
during systole, the variations in pressure have an effect on the resistance of the flow
passing through that area. Further, compliance of the collapsible tube allows for volume
changing features to be applied, like those proposed by Spaan et al.’s IMP model [31].

Figure 2.6 Schematic of in vitro setup by Gaillard et al. [36]

Unlike Pantalos et al., Gaillard et al. gave attention to the in vivo validation of his
experiment’s results. They used clinical echo measurements from the left anterior
descending coronary artery under various levels of aortic valve stenosis to compare
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against their results [36]. They found that their waveform of arterial coronary flow was
both accurate in shape and magnitude. This clinical validation method is important in
determining whether the model is accurate, especially if the parameters of the system are
going to be extrapolated beyond the comparable results. And while the model appears to
present a reliable results, the method of how they adjusted the RLV is unclear. However,
while passing a connecting tube to a VAD is unfeasible for the Hang MCS, the idea of
bringing the ventricular pressure to the coronary model was noteworthy.
A final in vitro model studied was by Calderan et al. [37]. The purpose of their work
was to develop a systemic model that could simulate the effects of “transcatheter aortic
valve implantation (TAVI)” [37] on coronary flow. Their entire system was composed of
a LV and aorta branch, a systemic impedance to help control the aortic waveforms, and
the coronary circulation. The coronary branch was modeled as the simplified LPN seen in
Figure 2.7a. It is composed of a proximal static resistance, compliance, and a distal timevarying resistor (Rma) [37].

Figure 2.7 Calderan et al.’s (a) coronary LPN, (b) Rma(t) resistance graph for one cardiac cycle,
and (c) experimental results of coronary flow and aortic pressure, and in vivo coronary flow [37]
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The time-varying resistor in Figure 2.7 was achieved using a “stepper motor”
connected to an “adjustable stopcock valve” [37]. The amount the valve was closed, the
amount of resistance to coronary flow, depended on the signal of Rma, which had a higher
value during systole than in diastole (Figure 2.7b) to mimic cardiac contraction impeding
the flow. The signal was sent to the stepper motor by a LabView system. Higher
magnitudes of resistance correlated with the stepper motor closing the valve more [37].
The coronary flow based on this time-varying resistance model can be seen in Figure
2.7c. As shown, it is in comparable qualitative agreement with the provided clinical
reference, however slight amplitude differences are apparent. Further, this model was
said to measure the coronary flow distal to Rma [37]. This means that attention was not
given to the proximal flow conditions, which may or may not have been physiological.
Since the study was to see the effect the TAVI had on coronary flow, the unknown area
between the TAVI and measured coronary flow could have had non-physiological
features that could interfere with the results. Additionally, this model did not account for
a relation of intramyocardial tissue pressure and coronary vessel compliance in the way
that Spaan et al. proposed to make distinctions between arterial and venous flow [31].
However, the control of the resistance using LabView is noteworthy considering the
same program is used in Hang’s setup [28].
Overall these models provide helpful insight into the methods used to capture
physiological coronary flow waveforms. Considering these experimental techniques,
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attention was then given to the LPN that would be used as the blueprint for the in vitro
system.
Selecting the Coronary Circulation LPN
When determining the framework of the LPN, it was important to consider the
implications of the experimental model used in relation to other Norwood in silico
models. A model based on a LPN that is very different from those in silico versions
might not provide the ability for comparable coronary results, in case one system’s
response was different from another. Therefore, the LPNs from multiple in silico models
[9–11, 27, 38, 39] of the Stage 1 with mBTS palliation were analyzed with regards to
their waveform results, size, and ease of implementation .
The in-depth review of the in silico models revealed a familial relationship between
the LPNs of the coronary circulations with slight variation through the other branches.
Dating from 2005 to 2014, the same coronary LPN was used between the works of
Lagana et al., Migliavacca et al., Bove et al., Hsia et al, Moghadam et al., and Corsini et
al. [9–11, 27, 38, 39]. Lagana et al. was the first to depict the coronary model in a
Norwood model [11]. They built their coronary LPN based on the descriptions by
Mantero et al. [13], whose adult-human mathematical model followed the ideas of Spaan
et al.’s IMP model [31]. A schematic of the coronary LPN used by these Norwood in
silico works is shown in Figure 2.8.
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Figure 2.8 Schematic of the LPN used in multiple in silico Norwood models

The “SVP” in Figure 2.8 refers to the single ventricle pressure (SVP). For the
Norwood palliation, this would refer to the systemic RV pressure, which is connected at
the SVP point from the heart model of their LPN. The compliance CCB connected to the
SVP mimics the idea of myocardial contraction, which, according to Mantero et al., is felt
more in the distal endocardial vessels than the proximal epicardial vessels [13]. Thus, the
SVP mostly affects the pressure at the CB resistance and compliance junction, and its
impact is decreased from the CA2 impedance to the CA1 impedance.
The different impedance elements in Figure 2.8 allow for the distinction between the
arterial coronaries (CA1 and CA2) and the venous (CB and CV). Hence, like the IMP
model, both arterial and venous blood flow should be distinguishable based on the point
that is measured. To provide the boundary condition to the 3D model in the MCS, it is
only necessary to create an arterial coronary blood flow and pressure. However, having
the ability to distinguish differences in arterial and venous flow may aid in validating the
waveforms.
To the author’s knowledge, all coronary LPN models for the Norwood palliation are
of the same structure. And so, it was determined that the LPN in Figure 2.8 would be the
reference for the in vitro model. A slight variation from this model was caused by the
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values of the resistors and compliances used in the in silico models (Table 2.1). Note that
the values for each element in the LPN are scaled based on body surface area (BSA) [40].
Each model uses the same elemental values because BSA remained at 0.33 m2.
Table 2.1 The LPN values used by the in silico models [9]–[11], [27], [38], [39]
Resistance (R)
[mmHg.s/mL]
Compliance (C)
[mL/mmHg]

CA1

CA2

CB

CV

10.6739

10.6739

21.3477

10.6739

1.94351 x 10-3

5.18269 x 10-3

7.77404 x 10-3

0.5 x 10-4

Referring to Table 2.1, relative to the R and C values used for the other systemic and
pulmonary circulations, the compliance values are magnitudes smaller and the resistances
are very large. In particular, the CV compliance is a magnitude smaller than the three
proximal to it. For experimental modeling feasibility, CCV was discarded and the
resistance, RCV, which was not negligible, was lumped into RCB. The final LPN and
values used for the in vitro model are seen in Figure 2.9 and Table 2.2.

Figure 2.9 The coronary LPN used for the in vitro model

Table 2.2 The LPN values for the LPN seen in Figure 2.9
Resistance (R)
[mmHg.s/mL]
Compliance (C)
[mL/mmHg]

CA1

CA2

CB

10.6739

10.6739

32.0216

1.94351 x 10-4

5.18269 x 10-4

7.77404 x 10-3
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The following section details the experimental implementation and reasoning for
discarding CCV. Along with CCV being eliminated, the compliances CCA1 and CCA2 were
reduced in size. A purely mathematical model, created for verification purposes, did not
couple a 3D model to the LPN. And so, there were slight differences in how the coronary
system responded. Reducing these compliance values achieved a physiological flow
waveform, details of which are discussed in the next chapter.
Creating the In Vitro Coronary Circulation
The methods chosen for creating the physical realization of the LPN were based on
those used by Vukicevic et al. [41] and Hang [28]. Tubing was used to connect the inflow
and outflow ports of the 3D model to the in vitro LPN. The amount of tubing was
minimized to reduce any effects of inertance and unintentional resistance. To set the
resistance, pinch needle valves were used, which cause a change in flow for a give
pressure drop based on Equation 2.1
𝑅 = ∆𝑃/𝑄

(2.1)

Here, Q is the flow rate through the valve and ∆𝑃 is the fluid pressure drop across the
valve. Additionally, the compliance of an impedance element is based on Equation 2.2.
𝐶 = ∆𝑉/∆𝑃

(2.2)

For this fluid system, the effects of C can be described by the change of volume (∆𝑉)
of fluid in the compliant element for a change in fluid pressure (∆𝑃) [41]. This is created
using air chambers that trap a pocket of air [41] coupled to the fluid system which applies
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the pressure that compresses the air. For setup purposes, the volume of air is calculated as
V=C*Pabs, where Pabs is the mean absolute pressure of the air at that compliance element.
The first two compliances (CCA1 and CCA2) were made using 10 mL syringes. Based
on Equation 2.2, the volume of air calculated for the CCV value was less than what could
be reliably measured. It was assumed that the compliance of the tubing was enough to
implement this feature. On the other hand, the compliance at CCB presented its own
complication since it is coupled to the SVP
The aim of the in vitro coronary model was to mimic the LPN as closely as possible.
Methods such as Geven et al.’s [34], where the coronary tubing was passed through the
LV chamber, were used as reference in designing the final model but not exactly
replicated. Geven et al.’s methods presented a three-dimensional effect of SVP on the in
vitro coronary LPN. Since this part of the system is supposed to be 0-D, the coronary
tubing needed to be affected by SVP at a specific point. This was achieved with the CCBSVP coupling chamber (CC) apparatus (Figure 2.10).

Figure 2.10 Schematic of the experimental CCB-SVP coupling chamber (Left) and LPN (Right)
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In Figure 2.10, a pneumatic SVP signal is applied to the air-filled side of the CC. This
signal is then translated across a diaphragm to the fluid chamber of the CC. This chamber
is connected to the main coronary tubing at the CB pressure point (PCB). By minimizing
the SVP contact to a point within the main coronary tubing, control of PCB for tuning
purposes is maintained. Throughout the cardiac cycle, as the SVP is applied, the
diaphragm will appropriately flex to affect PCB accordingly. The flex of the diaphragm
accounts for volume displacement, allowing for the variation in arterial and venous flow
as described by Spaan et al. The final in vitro coronary circulation is seen in Figure 2.11.

Figure 2.11 The in vitro coronary circulation

The CC was made of PVC pipe and fittings. The diaphragm’s material, a silicone
rubber, was chosen with respect to how it interacted with the fluid chamber. Thus, the
diaphragm’s compliance was CCB. Furthermore, a 3-way valve (Model: 225B-111CAAA,
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MAC Valve, Dundee, MI, USA) was used to connect an incoming compressed air line
and vacuum line with the output going to the SVP. Pressure regulators were used to
control the magnitude of the incoming pressure and vacuum pressure. The ratio of time
for compressed air to vacuum was sent to the 3-way valve as a computer generated signal
from the data acquisition/control system (DAQ) and LabVIEW (USB 6211, LabVIEW
8.6; National Instruments, Austin, TX). A schematic of this setup is shown in Figure
2.12.

Figure 2.12 Schematic of the setup used to create the pneumatic SVP signal

Coronary flow (QCOR) measurements, using a 5.1mm diameter electromagnetic flow
probe (Model: EP616-STD-PV8-501, Carolina Medical Electronics, King, NC), were
taken between the 3D model and the first impedance to ensure the proper arterial
boundary condition was met. Pressure measurements were taken at the syringe-tubing
unions (PCA1 and PCA2) and at the CC-tubing union (PCB). Wall taps were connected to
pressure transducers (DTXplus, BD Medical Systems, Sandy, UT). All signals were
acquired using the DAQ at 160 Hz. Full details of system equipment, setup, and tuning
can be found in Appendix A.
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CHAPTER THREE
THE IN VITRO MOCK CIRCULATORY SYSTEM
The In Vitro Model
A LPN of the entire cardiovascular system, with the addition of the coronary
circulation, was created based on the structure of Hang’s LPN [28]. The MCS features
the LPN coupled to a 3D model (test section) of the reconstructed aortic arch. A
schematic of the MCS is shown in Figure 3.1 (Left) and a photograph of the MCS is
shown in Figure 3.2 (Right). A VAD is used as a hydraulic pump whose output passes
through a proximal compliance (Cprox) to provide the input aortic flow (QAO) and pressure
(PAO) to the test section. From the test section, the fluid passes into the systemic
branches: upper body (UB), lower body (LB), and coronary (COR), and a
pulmonary/mBTS (mBTS) branch. All circulations return the fluid into the atrium (Atr)
that then reconnects to the VAD.
To run experiments with this system, the first step was to tune the in vitro LPN’s
resistance and compliance. These impedance values were determined by either an
analytical model or clinical data. Once tune, the VAD and proximal compliance (CPROX)
were adjusted to create the appropriate input aortic pressure waveform. With the
impedance downstream of the test section set, once the correct waveform was created,
then the resulting flows and pressures were measured.
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Figure 3.1 The MCS schematic (Left) and in vitro MCS (Right): (A) VAD, (B) Proximal Aortic
Compliance, (C) Test Section, (D) Upper Body, (E) CC and Coronary, (F) Lower Body, (G) Atrium,
(H) mBTS and Pulmonary. Points of flow (Q) and pressure (P) measurements.

Similar to the coronary in vitro model, air chambers and pinch needle valves were
used as compliance and resistance in the other systemic and pulmonary branches. The
atrium was assumed to have infinite compliance and was left as an open reservoir. All
flow measurements (referenced markers in Figure 3.1) were taken using electromagnetic
flow probes (EP600 series, Carolina Medical Electronics, King, NC) controlled by an
analog flow meter (FM501, Carolina Medical Electronics, King, NC). Pressure
measurements were taken at pressure wall taps (referenced markers in Figure 3.1). The
signal was acquired using pressure transducers (DTXplus, BD Medical Systems, Sandy,
UT) and passed through a bridge amplifier (Model 2100, Measurements Group Inc.,
Raleigh, NC). Both flow and pressure signals were measured and recorded using a data
acquisition system (DAQ) and LabVIEW (USB6211, LabVIEW 8.6; National
Instruments, Austin, TX). Compressed air and vacuum were used to control the VAD,
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similar to the system that created the coronary system’s SVP. Both systems used the
same air and vacuum lines but were independently controlled for systolic time ratio.
The Methods to Verify
In order to verify that the in vitro MCS was setup correctly, a purely mathematical
model of the LPN (Appendix B) of Figure 3.1 was created. This analytical model was set
up for a baseline case using parameter values from Corsini et al.’s LPN [10], whose
values were derived from pre-Glenn patients’ catheterization data. Then, with a
prescribed aortic flow and pressure input, the analytical model’s LPN provided the flow
and pressure measurements for the subsequent circulations. These were used for setting
the resistance and compliance of the MCS, controlling the VAD to achieve the desired
aortic waveforms, and controlling the air pressure of the SVP. A saline solution (30 cc
salt per gallon of water) was used as the system’s fluid. The heart rate (HR) was 120
beats per minute (bpm), which correlated to a 0.5 second cardiac cycle.
A generalized HLHS post-Norwood 3D model used by Corsini et al. [10] was
provided. The model (Figure 3.2) has a 3.5 mm inner diameter mBTS connected at the
innominate artery, and a representative coronary artery (2 mm inner diameter) at the site
of the DKS anastomosis. The test section was printed in 3D and used for the verification
study only. The 3D model was based on a BSA of 0.33 m2. Based on the scaling laws
defined by Pennati and Fumero [40], the coronary LPN values from Table 2.2 did not
change. A full set of LPN values and system tuning details are found in Appendices A
and B.
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Figure 3.2 The 3D-printed test section for the verification study: (A) Left to Right: Left
Subclavian (LSA), Left Carotid (LCA), Innominate (Inom), (B) Ascending Aorta (AO), (C)
Descending Aorta to Lower Body (LB), (D) mBTS, (E) Coronary (COR)

Verification Results
The system was set for the flow and pressures from the analytical model (Appendix
B). The experimental (or MCS) mean pressure (P) [mmHg], mean flow (Q) [Lpm], and
resistance (R) [WU = mmHg/Lpm] results can be seen alongside the analytical values in
Table 3.1. All MCS results were averaged over 10 cardiac cycles worth of data to ensure
stable results. A t-test at 95% confidence was performed to compare mean MCS and
analytical results. Methods for statistical analysis and uncertainty are found in Appendix
C. The resistance values were calculated using Equations 3.1-3.5. MCS and analytical
waveform relationship was quantified through the coefficient of determination (R2) and a
range-normalized Root-Mean-Square Error (σ) (Equation 3.6). Full results are in
Appendix D.
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Table 3.1 Mean flow, mean pressure, and resistance results for the verification study. MCS values =
mean ± uncertainty
Flow [Lpm]

Analytical

MCS

Cardiac Output (QAO)

1.82

1.82 ± 0.01

Upper Body (QUB)

0.38

0.38 ± 0.01

Lower Body (QLB)

0.40

0.40 ± 0.01

Pulmonary (QmBTS)

0.98

0.98 ± 0.01

Coronary (QCOR)

0.056

0.056 ± 0.002

Analytical

MCS

Ascending Aorta (PAO)

60.11

60.37 ± 0.30

Pulmonary (PPul)

11.06

11.05 ± 0.06

Lower Body (PLB)

56.71

57.56 ± 0.29

Coronary CA1 (PCA1)

53.61

57.51 ± 0.28

Coronary CA2 (PCA2)

43.71

43.89 ± 0.22

Coronary CB (PCB)

33.80

33.61 ± 0.18

Resistance [WU]

Analytical

MCS

Upper Body (UBSVR)

148

150 ± 4

Lower Body (LBSVR)

139

140 ± 3

mBTS (RmBTS )

50

50 ± 1

Pulmonary (Rpul)

7

7 ± 0.1

1000

1005 ± 35

Pressure [mm Hg]

Total Coronary (RTC)

𝑈𝐵𝑆𝑉𝑅 = (𝑃!" − 𝑃!"# )/𝑄!"

(3.1)

𝐿𝐵𝑆𝑉𝑅 = (𝑃!" − 𝑃!"# )/𝑄!"

(3.2)

𝑅!"#$ = (𝑃!" − 𝑃!"# )/𝑄!"#$

(3.3)

𝑅!"# = (𝑃!"# − 𝑃!"# )/𝑄!"#$

(3.4)

𝑅!" = (𝑃!" − 𝑃!"# )/𝑄!"#

(3.5)
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Table 3.1 shows the experimental (MCS) mean results are in good agreement with the
analytical model. A 30 mm circumference flow probe was used to measure QAO, QUB,
QLB and QmBTS. A 15 mm circumference flow probe was used to measure QCOR. The
probe sizing and relative magnitude of flow velocities resulted in less uncertainty for the
coronary flow, details of which are discussed in Appendix C. The t-test results do not
show any significant difference (p > 0.05) for the flow measurements.
For pressure, only the pulmonary pressure was found to have no statistical difference
(p=0.25) between the mean analytical and MCS values. However, PAO, Ppul, PCA2, and PCB
were encompassed in the uncertainty of MCS results and so the values were deemed
acceptable. The largest difference was found at PCA1, with a relative error of less than 8%.
This difference may be the result of comparing a purely analytical model whose
impedance was not able to capture that of the multi-scale model’s 3D test section.
Therefore, the results obtained were deemed sufficient. This can be shown further when
comparing PAO’s analytical and MCS waveforms (Figure 3.3).

Figure 3.3 Analytical and in vitro waveforms of aortic pressure (Pao) (R2=0.91, σ=8.6%)
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The aortic pressures for the analytical and MCS waveforms are highly correlated
(R2=0.91, σ=8.6%). The proximal compliance was calculated to be 0.094 mL/mmHg
compared to the analytical value of 0.095 mL/mmHg, and the pulse pressures were
within 1% of each other. The PAO is the input boundary condition to the test section and
governs the response of the subsequent circulations. As Table 3.1 indicates close
agreement with the analytical and MCS values for those subsequent circulations, it can be
concluded that the MCS’s impedance was appropriately set. Even more so, the addition
of the coronary branch did not seem to negatively affect the performance of the other
circulations. Those parts of Hang’s MCS [28] were replicated. It was then important to
verify that the in vitro CBF model was acting correctly alongside the rest of the system.
Verification of the Coronary Blood Flow Waveform
The aim in verification is to produce the analytical results using the MCS. However,
it is important that these results are consistent with what might be found clinically. While
echos of healthy coronary blood flow have been shown, it is important to consider that
HLHS patients may present abnormal flow. However, HLHS and congenital heart disease
patients’ coronary flow reveal the same general characteristics previously described. This
can be seen in the following image of the flow velocities in an epicardial coronary artery
of a neonate with HLHS and coronary fistulas: pathways from coronary vasculature into
the ventricle [33].
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Figure 3.4 Doppler echos of epicardial coronary arteries in HLHS neonate [33].

In Figure 3.4, the “S” and “D” stand for systole and diastole, respectively. It can be
seen that the flow is primarily forward (antegrade) toward the heart in diastole. While
systole, particularly in this case, the flow is primarily retrograde. Roberson et al. explains
that this particularly high systolic retrograde flow may be the result of the fistulas, which
aren’t always present in HLHS patients [33]. This reveals that CBF characteristics are
unique to the patient and measurement site. This is seen when comparing Figure 3.4 to
Figure 3.5.

Figure 3.5 Right coronary artery flow velocities for congenital heart disease patients [42].

In Figure 3.5, the right coronary artery flow velocities are both different when
compared against each other, and even more so when compared to Figure 3.4.
Nonetheless, the same pattern persists. The common characteristics for HLHS patient
arterial CBF include low systolic flow, early retrograde systolic flow, dominant diastolic
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flow, and peak flow at the beginning of diastole [16, 21, 33]. The goal of the in vitro CBF
waveform created is to provide a representative arterial coronary boundary condition to
the test section. With this in mind, the analytical and in vitro waveforms (Figure 3.6) are
both in agreement with the coronary flow characteristics, as well as with each other.

Figure 3.6 Analytical and in vitro coronary flow for the verification study (R2=0.83, σ=14.7%)

The CBF waveforms in Figure 3.6 both show retrograde flow during systole, peak
flow at the start of diastole, and a downward-trending flow through the rest of the cardiac
cycle. Furthermore, the MCS QCOR clearly indicates a majority of the arterial CBF occurs
in diastole. Therefore the shape of QCOR in relation to the cardiac cycle is acceptable as it
agrees with literature references for CBF. Additionally, no significant difference (p=0.85)
was found between the analytical and MCS mean values, and a correlation between the
data was strong (R2=0.84, σ=14.7%). This indicates an agreement between the analytical
coronary model and the in vitro coronary model.
From Figure 3.6, deviations in the magnitude of the retrograde systolic flow and slope
of the descending diastolic flow do exist between the analytical and MCS QCOR. The
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variation may be explained by the difference in pressure at PCA1 (Table 3.1), which may
indicate a difference in coronary impedance. To further understand the effect of
impedance on the CBF waveform and ensure that the CCB-SVP coupling (CC) would
respond appropriately to local changes, the following study was performed.
In Vitro Coronary System Verification
The aim of this study was to verify that the in vitro coronary system is an accurate
model of the LPN from Figure 2.9. The previous section ensured the system provided
physiological results that matched a specific analytical case. It was then important to see
if the model’s coronary hemodynamics would also respond to changes in the coronary
system with both accurate and physiological results. This was accomplished by assessing
three aspects of the system: the ability to produce arterial (QCOR) and venous (QCV)
coronary flow, the response to changes in CCB, and the response to changes in coronary
artery resistance (RCOR).
The system was again verified against the analytical model. The mean aortic pressure
was found to have no significant difference (p=0.16) at 95% confidence and the
waveform was well matched (R2=0.94, σ=10.2%). QCV was measured between the RCB
and the atrium tank (Figure 2.9) using a 30 mm circumference flow probe, which resulted
in larger uncertainty than QCOR, which used the 15 mm circumference flow probe.
Overall, the results (Table 3.2) reveal acceptable agreement.
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Table 3.2 Mean results for coronary system verification study. MCS values = mean ± uncertainty
Flow [Lpm]

Analytical

MCS

Cardiac Output (QAO)

1.82

1.81 ± 0.01

Upper Body (QUB)

0.37

0.37 ± 0.01

Lower Body (QLB)

0.40

0.40 ± 0.01

Pulmonary (QmBTS)

0.98

0.98 ± 0.01

Coronary Arterial (QCOR)

0.056

0.057 ± 0.002

Coronary Venous (QCV)

0.056

0.056 ± 0.005

Pressure [mm Hg]

Analytical

MCS

Ascending Aorta (PAO)

60.11

60.65 ± 0.43

Coronary CA1 (PCA1)

53.63

54.15 ± 0.79

Coronary CA2 (PCA2)

43.72

43.94 ± 0.39

Coronary CB (PCB)

33.82

33.53 ± 0.55

The test section used in the MCS only requires an arterial CBF boundary condition.
However, it is important to check that the coronary model can produce a venous CBF
because the coronary LPN (Figure 2.9) was taken from the in silico Norwood model
initially created by Lagana et al. [11]. Lagana et al. described creating the coronary LPN
based on an adult mathematical model by Mantero et al. [13], who used the IMP
methodology of Spaan et al. Thus, the in vitro coronary model was derived from the
methodology of the IMP model proposed by Spaan et al. [31], whose main purpose was
to accurately portray arterial and venous CBF. Testing reveals (Figure 3.7) that both
arterial and venous CBF can be measured in the in vitro model.
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a)

b)
Figure 3.7 Analytical and MCS (a) arterial QCOR (R2=0.86, σ=12.6%) and (b) venous QCV
(R2=0.85, σ=15.8%).

The waveforms for arterial QCOR (R2=0.86, σ=12.6%) and venous QCV (R2=0.85,
σ=15.8%) are in agreement with the analytical model. Furthermore, Spaan et al.
described venous CBF mainly occurring in systole and minimally in diastole [31]. They
explain that the coronary vessel’s compliance attributes to a blood volume displacement:
a diastolic filling of arterial CBF into the coronary bed, and a systolic emptying of that
blood through the venous vessels [31]. This agrees with the analytical and MCS
waveforms seen in Figure 3.7b: QCOR and QCV are at their maximums in diastole and
systole, respectively. Thus, the in vitro model is able to produce physiological venous and
arterial CBF.
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Once it was established that both arterial and venous CBF could be measured in vitro,
the versatility of the CC was assessed. This was accomplished by changing the
compliance (CCB) of the CC by using different diaphragm materials. The diaphragm
material’s compliance (CCB) cannot be directly measured, unlike air chambers whose air
volume corresponds to a specific compliance. However, physical interaction with the
material can reveal whether or not it is more or less flexible, which would mean more or
less compliance. Thus, the material is iteratively chosen to achieve the desired analytical
CBF waveform, which then correlates to an appropriately matched CCB.
For testing, three diaphragm materials were used: a 0.003-inch thick latex, a 0.040inch thick latex, and a 0.250-inch thick vulcanized silicone rubber. The flow measured
using the 0.040-inch latex material from the verification study is labeled as QCOR and QCV
and corresponds to the CCB value of 7.8E-3 mL/mmHg (Table 2.2). The more compliant
and thinner 0.0025-inch latex CBF is labeled as QCOR+C and QCV+C, and the less compliant
0.25-inch silicone rubber CBF is labeled as QCOR-C and QCV-C. For comparison to the
analytical model, a CCB value of 7.8E-2 mL/mmHg and a CCB value of 7.8E-4 mL/mmHg
were shown to display the CBF waveform’s response for more or less compliance,
respectively. The MCS results for more and less compliance are not being directly
compared to the analytical here. Instead, the comparison is the trend in which the flow
waveforms respond to the changes in compliance CCB. Through all testing, aortic pressure
and SVP were held constant. The results for arterial CBF are seen in Figure 3.8.
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a)

b)

Figure 3.8 Results of varying CCB for the (a) analytical and (b) in vitro arterial CBF (Qcor).

Both the analytical and MCS results (Figure 3.8a and 3.8b) display the same response
to changes in CCB. Increasing the compliance (from QCOR – C up to QCOR + C) results in
decreased systolic flow and increased diastolic flow. Physiologically speaking, if the
coronary vessels are more compliant (less stiff), then the intramyocardial pressure (or
SVP) would more easily compress the vessels, obstructing the flow during systole.
However, this more compliant vessel is then able to fill more during diastole. This is seen
with QCOR+C, which shows the most systolic retrograde flow and highest diastolic flow.
Then when compliance is decreased, as in with QCOR-C, there is less disrupted flow. For a
less compliant myocardium, the SVP would have less effect on the flow since the rigid
coronary vessels would not be as easily deformed under the intramyocardial pressure.
For venous CBF, Figure 3.9 shows that more flow occurs in systole for a more
compliant coronary system (QCV+C). This agrees with results shown in Figure 3.8 where
the most compliant CBF had the greatest diastolic flow. Hence, as Spaan et al. explained,
more venous CBF is ejected from the coronary bed in systole when diastolic arterial CBF
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is increased [31]. Additionally, the less compliant QCV-C interacts similarly to QCOR-C
where SVP appears to have minimal effect.

a)

b)
Figure 3.9 Results of varying CCB for the (a) analytical and (b) in vitro venous CBF (Qcv).

Next, the effect of resistance on the coronary circulation was evaluated. A flow
resistor (pinch-needle valve) was placed between the test section’s coronary artery and
the CA1 impedance. This coronary artery resistance (RCOR) was increased from the
reference setup while maintaining aortic pressure and SVP. The experimental and
analytical results of resistance and flow are shown in Table 3.3. The flows from the
reference setup are QCOR and QCV, while QCOR+Rcor and QCOR++Rcor indicate increased
resistance. Coronary artery resistance was calculated using Equation 3.7.
𝑅!"# = (𝑃!" − 𝑃!"! )/𝑄!"#

(3.7)

Table 3.3 Resistance and flow for the MCS and analytical models (Results = mean ± uncertainty)
Analytical RCOR
[WU]

MCS
RCOR [WU]

Analytical Flow
[Lpm]

MCS
Flow [Lpm]

QCOR

117

112 ± 2

0.056

0.057 ± 0.002

QCOR + Rcor

232

232 ± 2

0.050

0.049 ± 0.002

QCOR ++ Rcor

691

691 ± 5

0.036

0.035 ± 0.002
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The results of Table 3.3 had no statistical difference in their values (p>0.05). This is
shown further in Figure 3.10 where the analytical and in vitro waveforms were highly
correlated: QCOR+R (R2=0.87, σ=14.7%), QCV+R (R2=0.87, σ=18.3%), QCOR++R (R2=0.89,
σ=12.1%), and QCV++R (R2=0.90, σ=14.1%). This indicates that the in vitro model has an
accurate response to changes in coronary artery resistance using the flow resistor,
whereas the resistance could have also been implemented by changing the structure of the
test section’s coronary artery.

Figure 3.10 Arterial CBF for increasing RCOR for the (a) analytical and (b) in vitro models.
Venous CBF for increasing RCOR for the (c) analytical and (d) in vitro models.

For arterial flow (Figures 3.10a-b), increased resistance decreased the systolic
retrograde flow and decreased the total diastolic flow. For venous flow (Figures 3.10c-d),
the increased resistance had a subtle effect of decreasing the total flow throughout the
cardiac cycle. The overall effect was that total CBF decreased with increased RCOR, as
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shown by Table 3.3. This is to be expected as the act of increasing RCOR has been used to
model the effects of coronary artery stenosis. Mantero et al. modeled this in their study
where increased RCOR resulted in increased systolic and decreased diastolic arterial CBF,
with a total decreased CBF [13] (Figure 3.11).

Figure 3.11 Coronary artery flow with increased resistance indicated by the arrows [13]

The results from Figures 3.10 and 3.11 indicate the importance of coronary stenosis
and its effect on total CBF. For the present study, an addition of coronary stenosis
(increased RCOR), or impeding the coronary artery in any way, would result in highly
negative effects on the total CBF and thus myocardial oxygenation. This highlights the
sensitivity of the coronary circulation to any change in the local resistance of the aortic
arch and the importance of including it in the Norwood in vitro model.
Discussion
The verification study has shown that the in vitro MCS accurately reproduces the
results predicted by the analytical model when tuned to similar conditions. Specifically,
the in vitro coronary circulation produces physiological results for varying ranges of
RCOR and changes in CCB, indicating the versatility of the SVP-CCB coupling chamber.
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Once it was established that the MCS was a capable model, it was then necessary to
validate the model. A patient-specific study was used for this purpose.
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CHAPTER FOUR
VALIDATION OF THE IN VITRO MODEL
The System Setup
In order to validate the MCS, it must be able to reproduce clinical data pertaining to a
patient-specific setup (a LPN tuned to patient-specific impedance with an appropriate
input aortic pressure waveform). This patient-specific study is necessary to ensure the
MCS models physiological hemodynamics from which clinical implications can be
obtained. And so, data from a HLHS patient (MUSC2) who received a 3.5mm diameter
mBTS in the Norwood surgery was used for validation. A test section (Figure 4.1) was
made based on medical imaging data of the blood volumes to incorporate the patientspecific structural characteristics of the reconstructed aortic arch.

Figure 4.1 The MUSC2 3-D printed test section: (A) Descending Aorta, (B) LCA, (C) Innominate
artery, (D) mBTS, (E) Coronary artery

Figure 4.1 shows the 3-D printed MUSC2 test section of the reconstructed aortic arch.
Similar to the model used in the verification study, a representative coronary artery (2
mm inner diameter) was placed at the site of the DKS anastomosis (Figure 4.1 E). Any
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flow towards the DKS was assumed to go to the coronary circulation, similar to the
assumption by Corsini et al. [43]. Additionally, the MUSC2 model does not have an
LSA, which was disconnected during Stage 1 surgery. However, it is common for the
body to adjust for this change by creating connections at more distal points within the
vasculature [22]. And so, the resistance and compliance of the LSA was incorporated into
the LCA, resulting in the LPN of the MCS seen in Figure 4.2.

Figure 4.2 Schematic of the MCS used for the MUSC2 validation study.

The clinical data provides flow estimates for the cardiac output, upper body, lower
body, and mBTS/pulmonary. However, because coronary flow is not typically measured
in vivo during Stage 1 surgery, the flow had to be estimated. It was previously stated that
coronary flow is approximately 4% of the cardiac output [15]. This would result in
0.0504 Lpm for the MUSC2 QCOR. Additionally, Duncker et al. showed that QCOR per
gram of myocardium [mL/min-g] could be related to heart rate (HR) [bpm] using
Equation 4.1 [16].
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= 0.016 ∗ 𝐻𝑅 − 0.30

(4.1)

Rastin et al. also proposed that myocardium weight could be estimated based on
patient weight [44]. The MUSC2 patient had a weight of 5.4 Kg and so the estimated
myocardium weight was 30 g. Together with the heart rate of 120 bpm, the CBF was
calculated using Eq. 4.1 to be 0.486 Lpm. This value was approximately 3.9% of the
cardiac output for MUSC2. Based on the two methods of estimating CBF, an average of
the two results was taken, resulting in target QCOR of 0.050 Lpm for MUSC2. To account
for this flow in the cardiac output and satisfy continuity, the estimated QCOR was
subtracted from QUB and QLB equally. This was done because clinical data of cardiac
output and mBTS flow waveforms were to be matched in the validation study, whereas
upper and lower body flows were not. Adding or subtracting QCOR from the mean QAO
and QmBTS would have tainted the validation efforts, as well as change the target clinical
QP/QS.
The MUSC2 model has a BSA of 0.30 m2. The LPN values for the coronary
circulation (Appendix B) were scaled according to the methods proposed by Pennati and
Fumero [40]. The coronary resistance values and the estimated QCOR were then used to
estimate the mean pressures PCA1, PCA2, and PCB. The SVP minimum and maximum
pressures were adjusted based on the clinical mean atrium pressure and maximum clinical
systolic aortic pressure. Systolic time for the SVP was based on the notion that
ventricular pressure rises slightly before aortic pressure during isovolumetric contraction.
Additionally, the descent of the SVP was adjusted to cross the dichrotic notch of the
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clinical PAO. This completed the parameters necessary for setting up the MUSC2 coronary
circulation.
To account for the viscous effects of blood in the test section, a glycerin solution
(58% water and 42% glycerin) was used as a blood analog. This mixture resulted in a
density of 1096 kg/m3, a kinematic viscosity of 3.85 cS, and a dynamic viscosity of 4.21
cP. These values fell within clinical ranges for blood and those used by the in silico
Norwood studies [9, 10]. Additionally, the heart rate was 120 bpm, resulting in a 0.50
second cardiac cycle. All flow and pressure measurements were measured using the same
equipment and methods from the verification study (see Appendix A). The MUSC2 preGlenn catheterization and echo data were used to match aortic pressure, cardiac output,
and mBTS flow waveforms. Results were analyzed using the same methods proposed in
the verification study (See Appendix C for details).
Validation Results
The results of the MUSC2 validation study can be seen in Tables 4.1 and 4.2.
Statistically significant differences (p<0.05) are considered clinically insignificant if they
met the following criteria: mean pressure was within 1 mmHg of in vivo measurement or
if the mean flow’s uncertainty encompassed the clinical value. This was assumed because
in vivo flow uncertainty is unknown but usually taken to be within 10%, and pressure
measurement resolution is 1 mmHg.
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Table 4.1 Mean results of the MCS validation test compared against mean clinical values. and the
estimated mean coronary values. MCS values = mean ± uncertainty
Flow [Lpm]
Cardiac Output (QAO)
Upper Body (QUB)
Lower Body (QLB)
Pulmonary (QmBTS)
Pressure [mm Hg]
Ascending Aorta (PAO)

Clinical
1.26
0.31
0.32
0.58
Clinical
58.76

MCS
1.25 ± 0.01
0.30 ± 0.01
0.31 ± 0.01
0.58 ± 0.01
MCS
58.99 ± 0.30

Resistance [WU]
Upper Body (UBSVR)
Lower Body (LBSVR)
mBTS (RmBTS )
Pulmonary (Rpul)
Pressure [mm Hg]
Pulmonary (Ppul)

Clinical
170
166
80
10
Clinical
12.00

MCS
175 ± 6
169 ± 6
79 ± 1
11 ± 0.2
MCS
12.61 ± 0.06

Table 4.2 Mean results of the MCS validation test compared against the estimated mean coronary
values. MCS values = mean ± uncertainty
Flow [Lpm]
Coronary (QCOR)
Pressure [mm Hg]
Coronary CA1 (PCA1)
Coronary CA2 (PCA2)
Coronary CB (PCB)
Resistance [WU]
Coronary Artery (RCOR)
Coronary CA1 (RCA1)
Coronary CA2 (RCA2)
Coronary CB (RCB)
Total Coronary (RTC)

Estimated
0.050
Estimated
52.33
42.55
32.77
Estimated
129
196
196
535
1055

MCS
0.049 ± 0.002
MCS
51.86 ± 0.26
41.86 ± 0.21
30.39 ± 0.15
MCS
144 ± 6
203 ± 8
232 ± 10
494 ± 20
1073 ± 44

From Tables 4.1 and 4.2, the mean results are in good agreement and differences
considered insignificant based on the stated criteria. For instance, the cardiac output
(QAO) was found to have statistical difference in means (p<0.05), however the uncertainty
of the MCS value included the clinical reference value. Additionally, the QAO clinical and
MCS waveforms were reasonably correlated (R2=0.91, σ=9.9%). The QmBTS waveforms
were also highly correlated (R2=0.96, σ=13.5%) and found to have no statistical
difference in means (p=0.15). These flow waveforms are seen in Figure 4.3.
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Figure 4.3 Clinical and MCS aortic flow (R2=0.91, σ=9.9%) and mBTS flow (R2=0.96, σ=13.5%)

The MCS and clinical aortic pressure waveforms (Figure 4.4) also reveal high
correlation (R2=0.97, σ=6.0%). Mean PAO results did reveal statistical differences
(p<0.05), however the MCS value was within 1 mmHg of the clinical. Additionally, the
clinical and MCS aortic pulse pressures are 64.8 mmHg and 66.5 mmHg, respectively.
For the systolic portion of PAO, the clinical dP/dt is 838 mmHg/s and the MCS dP/dt is
824 mmHg/s.

Figure 4.4 Clinical and MCS aortic pressure waveforms (R2=0.97, σ=6.0%)

74

The proximal compliance (CProx) is used to provide compliance to the rigid test
section, and thus shape the aortic pressure waveform. The MSC CProx was measured to be
0.082 mL/mmHg. While there are no clinical compliance values available, scaling CProx
from the verification model would result in a value of 0.084 mL/mmHg. The similarity of
these values is noteworthy considering that the verification test section was derived from
the MUSC2 patient [10]. The additional MCS compliance values are seen in Table 4.3
where they are compared to the scaled compliance values of the verification LPN. CCB
scaled to a value of 0.0068 mL/mmHg, compared to the verification model’s CCB of
0.0078 mL/mmHg. The difference in values was determined to be indistinguishable
between different CCB materials and so the same 0.040-inch thick latex rubber was used
for CCB.
Table 4.3 Experimental compliance values of the validation study relative to scaled values from the
verification model. Compliance (C) [mL/mmHg]

MCS
BSA Scaled
MCS
BSA Scaled

CProx

CPul

CLB

CInom

0.082 ± .006

0.29 ± .08

0.081± .009

0.117± .011

0.084

0.34

0.069

0.078

CLCA

CCA1

CCA2

0.115 ± .008

0.00025 ± 0.00012

0.00050 ± 0.00013

0.078

0.00017

0.00046

As shown in Table 4.3, there are notable similarities in the validation MCS’s
compliance values and those estimated by the analytical model from the verification
study. This, along with the Table 4.1 results and the highly correlated waveforms,
supports the notion that the MCS is validated against clinical data. Additionally, the MCS
QCOR (Table 4.2) was found to have no statistical difference (p=0.51) from the estimated
QCOR. The resistances (Table 4.2) through the coronary circulation were well matched,
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resulting in coronary pressures consistent with the predicted values. Lastly, the QCOR
waveform displayed the same coronary flow characteristics that were expected. These are
seen in Figure 4.5 with respect to the aortic pressure and the arterial coronary pressure,
PCA1.

Figure 4.5 The QCOR waveform (Right axis) in relation to PAO and PCA1 waveforms (Left axis).

In Figure 4.5, QCOR during early systole displays a slight retrograde flow. As shown
by PCA1, this is caused by the increase in intramyocardial pressure during the
isovolumetric contraction of the cardiac cycle. In the isovolumetric time period there is
no cardiac output and the aortic pressure is low. Once the aortic flow starts, the aortic
pressure rises and offsets the coronary perfusion pressure to allow for an increase in
QCOR. However, it isn’t until diastole that the intramyocardial pressure drops and PCA1
falls substantially. This difference in PCA1 and PAO allows for the sharp increase in QCOR.
Consequently, the QCOR waveform for the validation case is physiologically accurate.
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Discussion
The clinical reference data was recapitulated by the in vitro MCS, all while
incorporating an in vitro coronary system that produced physiological results. It can
therefore be concluded that the MCS is a validated system. However, with regards to how
the coronary system is performing, a single validation case cannot define clinical
implications. The CBF was purely estimated and can only be used as a reference point.
To obtain meaningful relationships between the coronary flow and the rest of the MCS, a
parametric study must be performed.
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CHAPTER FIVE
MBTS PARAMETRIC STUDY
Purpose
The Norwood procedure using the mBTS is notorious for its negative effects on
coronary perfusion. In silico studies [8–11] have explicitly related mBTS size to coronary
perfusion pressure, flow, and the overall balance of pulmonary and systemic flow
(QP/QS), factors crucial to a Norwood patient’s survival. As previously mentioned, no in
vitro model has studied this relationship, which brings about the purpose of this
parametric study. By obtaining in vitro results for the effects of changing mBTS size on
coronary hemodynamics, the results can confirm or negate those presented by the in
silico models. These results, regardless of the agreement, can then be used for clinical
implications.
Testing Methods
The inner diameter of the mBTS was used as the varying parameter in this study. The
MUSC2 patient-specific test section and setup from the validation study (Figure 4.2) was
used as the reference case from which mBTS changes were made. As the reference
MUSC2 test section had a 3.5mm mBTS, two other models were created with a 3mm
mBTS and 4mm mBTS. These values are the typical sizes used in studies evaluating
mBTS size effects, and so they were used here for comparison to such studies [8–11]. It
is also important to note that because the validated MCS of a 3.5 mm mBTS patient used
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estimated coronary hemodynamics, the parametric study’s coronary results should only
be viewed relative to the 3.5 mm mBTS results.
The initial test was using the 3.5mm mBTS, and was essentially another validation
case. Then the test section would be interchanged with another of a different mBTS size.
The resistance, compliance, and atrium pressure of the 3.5mm test setup were held
constant throughout all test section changes. For the 3mm and 4mm mBTS models, the
first two cases studied were maintaining the mean aortic pressure and maintaining the
cardiac output of the 3.5mm mBTS case. By maintaining the aortic pressure and thus
upper body flow, this simulated the idea of constant cerebral perfusion (maintaining the
original blood flow to the brain). Any changes in aortic pressure were also adjusted-for in
the SVP: if peak systolic PAO increased/decreased, then SVP would increase/decrease
accordingly.
Under the same testing conditions, an additional study looked at maintaining the ratio
VP/CBF for all shunt sizes. This ratio (Equation 5.1) relates the ventricle power output
(VP) to the supply of coronary blood (CBF).
𝑉𝑃/𝐶𝐵𝐹 =

! !!
𝑃!" 𝑄!" (𝑡)𝑑𝑡
!! !

/𝑄𝐶𝑂𝑅

(5.1)

where tc is the time for one cardiac cycle, 𝑃!" 𝑄!" (𝑡) is the ensembled product of PAO
and QAO at each point in the cardiac cycle, and QCOR is the mean CBF.
The Norwood heart has limited myocardial oxygen reserve [12], meaning that there
isn’t much ability for the myocardium to extract more oxygen for the same amount of
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coronary blood provided. CBF provides the oxygen to the heart so that it can contract and
produce work. By maintaining the ratio of power output for a given amount of CBF, this
simulates the heart not working more or less for the amount of “energy” provided.
All testing for each shunt model was performed during the same testing session to
ensure consistency between the tuned system parameters and VAD. The same system
tuning and data recording methods as the verification and validation studies were used in
the parametric study (Appendix A). Results were analyzed using the previously stated
methods for the verification and validation studies (Appendix C).
Results for Constant Cardiac Output
Table 5.1 presents the results from the 3.5 mm mBTS setup. It was important to
obtain clinical validation of the MCS results before comparing to the 3 mm and 4 mm
mBTS results. In doing so, changes using the different sized shunts would be relative to
clinical values.
Table 5.1 Results for the 3.5mm mBTS system setup. MCS = Mean ± Uncertainty
Flow [Lpm]
Cardiac Output (QAO)
Upper Body (QUB)
Lower Body (QLB)
Pulmonary (QmBTS)
Pressure [mm Hg]
Ascending Aorta (PAO)
Pulmonary (Ppul)
Atrium (PAtr)
Resistance [WU]
Upper Body (UBSVR)
Lower Body (LBSVR)
mBTS (RmBTS )
Pulmonary (Rpul)

Clinical
1.26
0.31
0.32
0.58
Clinical
58.76
12
6
Clinical
170.2
165.9
80.1
10

MCS
1.27 ± 0.01
0.31 ± 0.01
0.32 ± 0.01
0.58 ± 0.01
MCS
58.63 ± 0.30
11.96 ± 0.06
6.02 ± 0.06
MCS
169 ± 5
164 ± 5
80 ± 1
10 ± 0.2

Flow [Lpm]
Coronary (QCOR)
Pressure [mmHg]
Coronary CA1 (PCA1)
Coronary CA2 (PCA2)
Coronary CB (PCB)
Resistance [WU]
Coronary Artery (RCOR)
Coronary CA1 (RCA1)
Coronary CA2 (RCA2)
Coronary CB (RCB)
Total Coronary (RTC)
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Estimated
0.050
Estimated
52.33
42.55
32.77
Estimated
129
196
196
535
1055

MCS
0.051 ± 0.002
MCS
52.83 ± 0.26
43.04 ± 0.21
32.28 ± 0.15
MCS
114 ± 4
193 ± 8
212 ± 8
517 ± 20
1055 ± 41

The mean results of Table 5.1 are in good agreement with the clinical and estimated
values, illustrating the MCS’s repeatability. No clinical significance in data was detected.
The PAO clinical and MCS waveforms were reasonably fitted (R2=0.90, σ=11.7%). The
QAO waveforms were well matched (R2=0.97, σ=7.3%), as were the QmBTS waveforms
(R2=0.95, σ=9.7%). These are seen in Figure 5.1.

Figure 5.1 Parametric study validation waveforms of QAO, QmBTS, and PAO.

Once it was established that the MCS was working under the correct clinical
conditions, the test sections were interchanged. Cardiac output was maintained by
adjusting the aortic pressure using the VAD and the resulting hemodynamics were
recorded (Table 5.2).
Table 5.2 Parametric study results for constant cardiac output. Mean results for flow [Lpm] and
pressure [mmHg]. (Bottom three rows) Percent change relative to the 3.5mm values.
mBTS
3 mm
3.5 mm
4 mm
mBTS
3 mm
3.5 mm
4 mm

QCOR
0.053 ± 0.002
0.051 ± 0.002
0.048 ± 0.002
QCOR
5%
-6%

QmBTS
0.56 ± 0.01
0.58 ± 0.01
0.61 ± 0.01
QmBTS
-4%
4%

QUB
0.33 ± 0.01
0.31 ± 0.01
0.30 ± 0.01
QUB
3%
-3%
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QLB
0.33 ± 0.01
0.32 ± 0.01
0.31 ± 0.01
QLB
3%
-3%

QP / QS
0.79
0.85
0.92
QP / QS
-7%
8%

PAO
61.8 ± 0.3
58.6 ± 0.3
55.2 ± 0.3
PAO
5%
-6%

From Table 5.2, increasing the mBTS from a 3mm to a 4mm size and maintaining the
cardiac output required a large decrease in the mean PAO to account for the decreased
total MCS resistance. Further, as shunt size increased, the QmBTS also increased while the
systemic circulation suffered. This is shown individually through the decreased QUB, QLB,
and QCOR, with the total effect shown by the large increase in QP/QS.
Additionally, all mean values of Table 5.2 were found to have significant difference
(p<0.05) between the different mBTS sizes. The most notable difference is seen in the
percent change of coronary flow. The variation in mBTS caused a span of 11% change
(from 3mm to 4mm) in QCOR. This disparity can better be seen in Figure 5.2 of the aortic
pressure, coronary flow, and mBTS flow waveforms.

Figure 5.2 Waveforms for PAO, QmBTS, and QCOR for the varying shunt sizes while held at
constant cardiac output.

Figure 5.2 shows that as the mBTS size increased, the systolic and diastolic QmBTS
increased. To maintain the cardiac output, the peak systolic PAO decreased while also
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decreasing the diastolic aortic pressure. Because the systolic PAO decreased, the SVP also
decreased its peak systolic pressure. Therefore, the difference in QCOR is not as evident
during systole. However, in diastole, because the diastolic aortic pressure decreased with
increased mBTS size, the diastolic QCOR also decreased due to the reduced perfusion
pressure, CPP. Seeing as QmBTS increased in the diastolic time period while QCOR
decreased, this indicates the “shunt stealing” [9] phenomenon.
Results for Constant Aortic Pressure
In a similar manner to the constant cardiac output study, results were obtained for the
different mBTS sizes while maintaining the mean aortic pressure. These results can be
seen in Table 5.3.
Table 5.3 Parametric study results for constant aortic pressure. Mean results for flow [Lpm] and
pressure [mmHg]. (Bottom three rows) Percent change relative to the 3.5mm values.
mBTS

QCOR

QmBTS

QUB

QLB

QAO

QP / QS

3 mm

0.051 ± 0.002

0.54 ± 0.01

0.31 ± 0.01

0.32 ± 0.01

1.22 ± 0.01

0.79

3.5 mm

0.051 ± 0.002

0.58 ± 0.01

0.31 ± 0.01

0.32 ± 0.01

1.27 ± 0.01

0.85

4 mm

0.050 ± 0.002

0.63 ± 0.01

0.32 ± 0.01

0.32 ± 0.01

1.32 ± 0.01

0.91

mBTS

QCOR

QmBTS

QUB

QLB

QAO

QP / QS

3 mm

0%

-7%

0%

0%

-4%

-7%

3.5 mm
4 mm

-

-

-

-

-

-

-1%

9%

1%

0%

4%

8%

The mean results of maintaining aortic pressure (Table 5.3) are not as dramatic as
those of maintaining cardiac output (Table 5.2). As the MCS’s resistance, except for the
shunt, stayed the same with each varying mBTS test section, maintaining aortic pressure
should result in no change in the mean flows to each region where resistance didn’t
change. Thus, the systemic flow results do not reveal any noteworthy differences. The
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only notable changes are with QAO, QmBTS, and QP/QS. In fact, when maintaining aortic
pressure, the relative change in QmBTS is much more noticeable. However, comparing the
QP/QS of Table 5.2 and Table 5.3, the same relative changes were achieved. This reveals
that regardless of whether the heart works to maintain cardiac output or aortic pressure,
the Qp/QS is highly sensitive to the mBTS size.
Results for Constant Ventricle Power per Coronary Flow
The results of maintaining the VP/CBF are seen in Table 5.4. The results of VP and
VP/CBF are also shown for the other cases. Note that VP/CBF for the constant cardiac
output case of the 3mm mBTS resulted in the same VP/CBF ratio as the 3.5mm mBTS.
Table 5.4 Parametric study results for constant SVP/CBF [J/L]. Mean flow (Q) [Lpm], Mean
pressure (P) [mmHg], Ventricle Power (VP) [mW]. Test results from the constant QAO and mean PAO
cases are denoted by “CO” and “P”, respectively. A * is used to denote constant VP/SVP (Bottom
three rows) Percent change relative to the 3.5mm values.
mBTS
3 mm P
3 mm CO *
3.5 mm
4 mm *
4 mm CO
4 mm P
mBTS
3 mm P
3 mm CO *
3.5 mm
4 mm *
4 mm CO
4 mm P

QCOR

QAO

PAO

QmBTS

QP/QS

VP

VP/CBF

0.051 ± 0.002
0.053 ± 0.002
0.051 ± 0.002

1.22 ± 0.01
1.27 ± 0.01
1.27 ± 0.01

58.8 ± 0.3
61.8 ± 0.3
58.6 ± 0.3

0.047 ± 0.002

1.25 ± 0.01

53.9 ± 0.3

0.54 ± 0.01
0.56 ± 0.01
0.58 ± 0.01
0.60 ± 0.01

0.048 ± 0.002
0.050 ± 0.002
QCOR

1.27 ± 0.01
1.32 ± 0.01
QAO

55.2 ± 0.3
58.8 ± 0.3
PAO

0.61 ± 0.01
0.63 ± 0.01
QmBTS

0.79
0.79
0.85
0.92
0.92
0.91

187.1
205.3
196.3
180.2
187.7
208.7

220.2
231.3
231.9
231.9
236.7
250.3

QP/QS

VP

VP/CBF

0%
5%
-8%
-6%
-1%

-4%
0%
-2%
0%
4%

0%
5%
-8%
-6%
0%

-7%
-4%
3%
4%
9%

-7%
-7%
8%
8%
8%

-5%
5%
-8%
-4%
6%

-5%
0%
0%
2%
8%

From Table 5.4, when maintaining VP/CBF and decreasing the shunt size to 3mm,
there is a 5% increase in CBF and ventricle power. However, there is a 7% decrease in
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QP/QS, which would result in a less oxygen saturation rates for the CBF. The combination
of decreased saturation rates and increased power are unfavorable for the single ventricle
heart. Likewise, when the mBTS is increased to 4mm, there is an 8% loss of CBF with an
8% decrease in VP. This also results in a drop (2% decrease) in cardiac output. Lower
QAO coupled with the increased (8%) QP/QS results in a drop in systemic blood flow,
which may be problematic for cerebral perfusion.
Lastly, consider if the heart were to attempt to increase CBF to the initial 3.5mm case
value, as in the “4 mm P” scenario. The heart would then have to increase VP by 6%,
resulting in an increase of the ratio VP/CBF by 8%. As the myocardium has limited
oxygen extraction reserve [12], it is likely unrealistic to consider this situation where the
heart would work harder for the same amount of CBF provided.
Discussion and Clinical Implications
The results of this in vitro study reveal that as shunt size (the inner diameter of the
mBTS) increases in a Norwood patient, the blood flow to the myocardium (CBF)
decreases. Figure 5.2 shows that CBF and diastolic PAO decrease with increasing mBTS
size. CBF is dependent on the CPP, as well as the ventricular contraction’s interaction
with the coronary vasculature [18]. In this study, changes in the ventricular contraction
are accounted for using the SVP-CCB coupling chamber by adjusting the SVP. That is
why Figure 5.2 did not reveal a substantial difference in CBF during systole; as systolic
PAO increased so did SVP. The real difference was in diastole where ventricular
contraction (and so SVP) has its least restraining effect on CBF, and CPP is the main
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dictator of how much QCOR there is. Thus, because diastolic PAO decreases with
increasing mBTS size, CPP decreases and there is less QCOR.
Table 5.4 shows that as mBTS size increases the ratio of pulmonary to systemic blood
flow (QP/Qs) also increases. While this may lead to a better balance of oxygenated and
deoxygenated blood in the Norwood patient, the myocardium is still receiving less blood
flow, particularly in the 4mm case of constant VP/CBF. The myocardium’s oxygen
extraction capabilities are limited [21]. So, in the condition that the heart would either
maintain a certain amount of cardiac output or maintain the VP/CBF after Norwood
palliation, a shunt too large in size would result in a relatively lower CBF.
In order to increase the CBF with the larger shunt, issues arise with the systolic PAO
and required ventricle power. This idea was shown through the constant aortic pressure
tests where coronary blood flow was maintained for the various mBTS sizes. While mean
PAO is the same between all shunt sizes, the aortic pressure waveforms reveal that systolic
pressure increases and diastolic pressure slightly decreases with increasing shunt size.
This can be seen in Figure 5.3 of PAO for various shunt sizes at a constant mean PAO.

Figure 5.3 Waveforms for PAO for the varying shunt sizes while maintaining the average PAO.
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In maintaining mean PAO and CBF, Figure 5.3 reveals the change in shunt size, and
thus impedance of the circulation, changes the form of PAO. The systolic PAO and SVP
increase with the larger mBTS. The increased SVP increases myocardial work and
oxygen demand [21]. This idea is also shown through the 6% increase in ventricle power
and 8% in VP/CBF from Table 5.5. So in the case where the heart attempted to maintain
a certain cardiac output there was less CBF. If the heart were to increase the CBF, then
the results reveal that the systolic peak, cardiac output, and thus power output would have
to increase. This idea is also illustrated with Figure 5.4.

Figure 5.4 Waveforms for PAO and QCOR for the reference 3.5mm shunt size and the 4 mm shunt
size. Labels with “PAO” are from the constant aortic pressure test and labels with “CO” are from the
constant cardiac output test.

Figure 5.4 shows that when the mBTS size was increased, CBF and PAO decreased for
the constant cardiac output case. When PAO was increased to achieve the same CBF as
the 3.5 mm mBTS case, the systolic PAO increased (“4 mm PAO PAO” in Fig. 5.4). From
Table 5.4, the 4mm mBTS with constant mean aortic pressure had a 6% increase in VP
and 8% increase in VP/CBF. This means that the heart would be working harder and
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demanding more oxygen for essentially the same amount of CBF as the 3.5 mm case.
This could result in a devastating cyclic reaction where the heart continues to work harder
to increase CBF but isn’t able to supply enough oxygen to the myocardium for the
amount of work performed. As the Norwood heart is already a single ventricle system
having undergone highly invasive modifications, it is advised that caution is given to how
mBTS size can affect CBF and ventricular function.
In silico studies [7–9, 11] have expressed the detrimental effects of the mBTS on
Norwood hemodynamics, in particular to coronary perfusion. Specifically, Table 5.5
shows that as mBTS size increases, coronary blood flow decreases and Qp/QS increases.
Table 5.5 In silico [7], [9], [11] and in vitro MCS results of varying mBTS size. Top three rows: Flow
(Q) [Lpm] and pressure (P) [mmHg]. Bottom three rows: Changes relative to the 3.5mm results.
mBTS
3 mm
3.5 mm
4 mm
3 mm
3.5 mm
4 mm
mBTS
3 mm
3.5 mm
4 mm
3 mm
3.5 mm
4 mm

Bove et al. [7]
QAO
PAO
QCOR
2.12
0.081
2.28
0.076
2.38
0.071
QAO
PAO
QCOR
-7%
7%
4%
-7%
Lagana et al. [11]
QAO
PAO
QCOR
2.123
84.56
0.082
2.275
79.83
0.076
2.387
75.67
0.071
QAO
PAO
QCOR
-7%
6%
8%
5%
-5%
-7%

QP/QS
0.72
1
1.26
QP/QS
-28%
26%

mBTS
3 mm
3.5 mm
4 mm

QP/QS
0.72
1.003
1.254
QP/QS
-28%
25%

mBTS
3 mm
3.5 mm
4 mm

3 mm
3.5 mm
4 mm

3 mm
3.5 mm
4 mm
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Moghadam et al. [9]
QAO
PAO
QCOR
2.09
0.0854
2.23
0.0796
2.35
0.0741
QAO
PAO
QCOR
-6%
7%
5%
-7%
in vitro MCS
QAO
PAO
QCOR
1.27
61.76
0.053
1.27
58.63
0.051
1.27
55.17
0.048
QAO
PAO
QCOR
0%
5%
5%
0%
-6%
-6%

QP/QS
0.726
1.004
1.302
QP/QS
-28%
30%
QP/QS
0.79
0.85
0.92
QP/QS
-7%
8%

These in silico results of Table 5.5 are consistent with the in vitro findings in the
present study, which reveals two important conclusions. The first is that since the in silico
results agree with the in vitro results, the in silico results are verified and can be used for
clinical implications. The second is that both results reveal the negative effects of
increasing mBTS size, which could lead to the demise of the Norwood heart.
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CHAPTER SIX
CONCLUSION
Conclusion
In completing this study, the objectives were evaluated for their level of
completeness, and the hypothesis analyzed as either accepted or rejected. The objectives
(1-5) and hypothesis (6) are re-stated here:
1. Design and integrate a coronary circulation into a previously validated in vitro
multi-scale model [28]
2. Verify the system’s response against a mathematical model
3. Validate the in vitro coronary blood flow against clinical findings in literature
4. Validate the entire in vitro model against clinical data of a HLHS patient
5. Investigate the effects of mBTS size on coronary perfusion
6. The in vitro model will illustrate how increased mBTS size negatively affects
coronary perfusion
The present study conducted tests on a mock circulatory system of the Norwood with
mBTS palliation. The MCS featured the pulmonary and systemic circulations from the
Hang [28] MCS. The history of coronary modeling was investigated and led to the
design of an in vitro coronary circulation that was implemented into the MCS,
completing objective #1. A mathematical model and clinical-based literature references
on CBF were used to verify the workings of the MCS and validate the coronary model,
completing objectives #2 and #3. A patient-specific test (MUSC2) was used to validate
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the MCS, completing objective #4. A patient-specific study that analyzed the effects of
mBTS size on the Norwood, and specifically coronary, hemodynamics was conducted,
completing objective #5. Thus, all five objectives were met.
In the mBTS parametric study, it was shown (see Figure 5.2) how increasing mBTS
size decreases the diastolic aortic pressure. The diastolic aortic pressure is part of the
coronary perfusion pressure, and so a decrease in diastolic PAO leads to a decrease in
coronary blood flow. Thus, a direct link between mBTS size and coronary perfusion was
found, and the result was that increased mBTS size does negatively affect (by decreasing)
the CBF. And so, the hypothesis is accepted.
Advantages, Disadvantages, and Future Work
The CBF was not validated against exact Norwood clinical data, but rather the best
insight as to what Norwood coronary hemodynamics would be. However, in the event
that clinical Norwood coronary data is obtained, the system could be operated to reflect
such data. Additionally, the MCS is an open-loop system; there is no feedback to the
VAD or RC components when applying distressing changes like increased mBTS size.
Aortic pressure or flow is held constant in these cases to best approximate how the
human body might respond. The in vitro MCS could be improved by adding
autoregulation using a feedback-controlled system. The system could be integrated into
the control of the VAD based on the flow and pressure in vitro measurements.
The MCS presented in this study is advantageous in that it is the first validated in
vitro system of the Norwood palliation to feature the coronary circulation. It allowed for
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verification of previous in silico studies through the mBTS parametric study. It can now
be used to investigate other variables that would affect Norwood coronary
hemodynamics, such as coarctation. Additionally, medical devices can be tested on this
platform to see their effect on CBF. For instance, DeCampli et al. evaluated the use of a
“counter-pulsation” device on the mBTS to improve coronary perfusion in neonatal pigs
[45]. To test this device on human Norwood hemodynamics, the device could be
implemented in the in vitro MCS. Comparison between the results obtained with and
without the device would reveal its effectiveness. Hence, the presented and potential
work of the in vitro MCS highlights the importance of an experimental setup in
continuing engineering breakthroughs for single ventricle palliations.

92

APPENDICES

93

APPENDIX A: EQUIPMENT AND SYSTEM CALIBRATION
Table A.1 lists all equipment used to create the MCS and for measurement taking.
Table A.1 Equipment used in in vivo MCS setup and data recording.
Equipment
Clear PVC pipe
Pinch-needle valves
Silicone rubber clear tubing
Barbed tube fittings

MCS

Plastic couplings (straight, T-joint, elbow)
Type 303 stainless steel hose barb
Metal wire
Ventricular-Assist Device (Excor®, Berlin Heart 25 cc, Berlin,
Germany)
Piezo pressure regulator (Type: PRE-U2, Hoerbiger, Schongau
Germany)
3-way valve (Model: 225B-111CAAA, MAC Valve, Dundee, MI,
USA)

Measurements

Pneumatic valve (at least up to10 psi)
Vacuum regulator
Electromagnetic probes (P600 series, Carolina Medical Electronics,
King, NC) (30mm and 15mm circumference)
Analog Flow Meter (Model FM501, Carolina Medical Electronics,
King, NC)
Pressure transducers (BD DTXplus, BD Medical Systems, Sandy,
UT)
Bridge amplifier (Model 2100, Measurements Group Inc., Raleigh,
NC)
DAQ card (USB NI-6211, National Instruments) and LabVIEW
software (USB 6211, LabVIEW 8.6; National Instruments, Austin,
TX)
Rigid plastic tubing and pressure taps
Vacuum and compressed air supply
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Purpose
Compliance air chambers. Sized as
needed
Resistance elements
Connections between resistance,
compliance, test section, and VAD.
Sized as needed.
Connect tubing to compliance air
chambers
Connect LPN tubing
Grounding connection to LPN
Grounding connection from SS
hose barbs to Atrium tank and flow
meters
Create input flow to test section
during pulsatile flow
Control of vacuum pressure to
VAD
Alternate high pressure and vacuum
to VAD and CC. Timing is
controlled by LabVIEW.
Control of high pressure to VAD
and CC
Control of vacuum to CC
Flow measurements
Flow measurements
Pressure measurements
Pressure measurement’s voltage
nulling and amplification
Data acquisition from pressure
transducers and flow meters.
Sampled at 160 Hz.
Connections from LPN to pressure
transducers
VAD control

The architecture of the MCS and equipment setup is seen in Figure A.1.

Figure A.1 Schematic of MCS and equipment setup.

The following is the step-by-step procedure for pressure transducer calibration:
1. Set the test section’s ascending aorta as the datum height
2. Set all pressure taps connected to pressure transducers at the datum height
3. On the pressure transducers, set the black mark at the datum height
4. Fill a clear beaker with water and set the top of the water at the datum height
5. Connect a rigid plastic tube from the pressure transducer to the water in the
beaker, ensuring that water fills the tube completely
6. With the bridge amplifier turned on and LabVIEW showing the pressure signal,
adjust the amplifier’s balance until the pressure reading is zero
7. Apply a known hydrostatic pressure to the beaker and adjust the amplifier’s gain
until the correct reading is shown on LabVIEW
8. Repeat for multiple different hydrostatic pressures and all pressure transducers
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The following is the step-by-step procedure for flow meter calibration:
1. Turn on flow meter at least 30 minutes prior to use
2. Ensure all flow probes are filled with a saline solution (30 cc salt/ gallon H2O)
and there is no movement of the fluid in the probes
3. Ensure grounding wires from LPN are connected to grounding cables from
flow meter
4. Ensure the flow probe’s probe factor is correctly set on the flow meter by
using the appropriate PFX value and Probe Factor dial
5. Set the Range dial to the range of flow appropriate to the flow
6. Turn the Balance dial to 500
7. With the main dial set on OFF, turn the Zero dial until the analog reading on
the flow meter is zero
8. After 30 minutes and with fluid-filled probes, turn the flow meter’s main dial
to Null and adjust until the analog reading on the flow meter is at its lowest
value
9. Turn the main dial to Balance and adjust the Balance dial until the reading on
LabVIEW is zero
10. Turn the main dial to + and, if necessary, adjust the Balance dial until the
reading on LabVIEW is zero
11. Measurements can now be taken with the dial set to +
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The following is the step-by-step procedure for tuning the MCS to a desired test setup:
1. Ensure all flow probes and pressure transducers are calibrated prior to tuning
2. Adjust compliance air chambers to correct air volumes
3. Ensure all pressure tubing from pressure transducers to pressure taps in LPN are
filled with fluid
4. Using a head tank connected directly to the LPN’s CPROX, set the head tank’s fluid
height to the hydrostatic pressure of the mean PAO (This is a steady flow setup in
which the VAD is disconnected and the flow from the Atrium tank is pumped up
to the head tank)
5. Adjust resistance valves until the correct flows and pressures are measured in
each circulation
6. Once the correct flows and pressures are tuned, disconnect the head tank setup
and connect the VAD with the VAD’s outflow port going towards CPROX and the
inflow port connected to the Atrium tank (minimize distance between each
connection)
7. Ensure the air pressure connection to the VAD is disconnected and that the 3-way
valve is turned on and switching back and forth between the compressed air and
vacuum pressure lines (switching rate determined by systolic-time ratio
designated in LabVIEW)
8. Apply compressed air and vacuum pressure to the setup
9. Slowly connect the air pressure connection to the VAD and track the pressure
measurement taken between the 3-way valve and VAD. This pressure must not

97

fall outside the range of -80 to 250 mmHg for VAD safety. Adjustments to
pressure and vacuum regulators will have to be made to apply appropriate
pressure to VAD and achieve the desired mean aortic flow and pressure.
10. Get rid of any air bubbles in the MCS tubing
11. Adjust the MCS’s CPROX to help form the desired PAO and QAO
12. Adjust the SVP’s air pressure and compressed air to apply the appropriate
ventricle pressure to the SVP-CCB compliance chamber (CC)
13. Once the appropriate input PAO is applied to the test section and the appropriate
SVP applied to the CC, record the resulting pressures and flows using LabVIEW
Following the previous 13 steps, the following is the step-by-step procedure for
performing a parametric test in the MCS:
14. Once the initial setup is tuned and data recorded, disconnect the air pressure from
the VAD, allowing all flow to stop
15. Carefully clamp all tubing connections to the test section and remove the test
section from the MCS
16. Connect another test section to the MCS. It is critical that the same position the
previous test section was in is now used for the new test section and that no
changes to resistance or compliance are made.
17. Unclamp tubing connections and get rid of any air bubbles
18. Repeat steps 9-13 for each new test section
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APPENDIX B: ANALYTICAL MODEL
A schematic of the verification analytical model is seen in Figure B.1. For the
analytical model, the inputs were the aortic pressure, aortic flow curve, and the single
ventricle pressure curve. In Figure B.1, the VAD represents this implementation.

Figure B.1 Schematic of analytical model used for verification. Created by and printed with
permission of Dr. Tim Conover of Clemson University.
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Table B.1 shows the LPN values used in the analytical model for the verification study
and Table B.2 shows the coronary LPN values used in the MUSC2 validation study.
Table B.1 LPN values used in the analytical model. Pressure (P) [mmHg], Compliance (C)
[mL/mmHg], Inertance (L) [mmHg.s2/mL], Resistance [mmHg.s/mL]
Heart

Systemic Circulation

PAtrium

4.1

Linom

0.06919

CAO

0.095

Rinomp

2.982

Cinom

0.0888

Coronary Circulation
Lcor

0.02801

Rinomd

14.517

Rcor

7.01

Llca

0.08783

Cca1

1.94E-04

Rlcap

2.754

Rca1

10.6739

Clca

0.0444

Cca2

5.18E-04

Rlcad

31.399

Rca2

10.6739

Llsa

0.07724

Ccb

7.77E-03

Rlsap

2.3541

Rcb

32.0216

Clsa

0.0444

Rlsad

26.8339

Pulmonary Circulation
Lshunt

0.04149

Rsvc

0.586

Rshunt

0.461

Llb

0.02276

Kshunt

0.14981

Rlbp

0.5097

CPA

0.3877

Clb

0.0779

RPA

0.4249

Rlbd

7.8291

Table B.2 Coronary LPN values for the validation study. Compliance (C) [mL/mmHg], Resistance
[mmHg.s/mL]
Coronary Circulation
Rcor

7.71

Cca1

1.71E-04

Rca1

11.7413

Cca2

4.57E-04

Rca2

11.7413

Ccb

6.85E-03

Rcb

35.2238
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APPENDIX C: STATISTICS AND UNCERTAINTY ANALYSIS
Statistics
The results of all testing were averaged over 10 cardiac cycles worth of data. A t-test
at 95% confidence was used to compare mean pressure and flow results. Waveforms of
MCS results and clinical or analytical results were analyzed using the coefficient of
determination (R2) (Equation C.1).
𝑅! =

!
!
! !
!!! !! !!" ! !!! !! !!! !!"
!
!
! ! ! (! )! !( ! ! )!
! !
!!!(!! ) !( !!! !! )
!!! !"
!!! !"

(C.1)

In Equation C.1, xi and xci denote the MCS and analytical or clinical value,
respectively, at the same time point in the cardiac cycle. Additionally, the waveform
results were analyzed using the normalized root-mean-square error (RMSE).

The

normalized RMSE was calculated using range (𝑥!"# − 𝑥!"# ) and mean values (𝑥) of the
result. The equations for these are seen in Equations C.2-C.4

𝑅𝑀𝑆𝐸 =

𝜎=!
𝜔=

!
!!!(𝑥!

− 𝑥!" )! /𝑁 ∗ 100%

!"#$

(C.2)

(C.3)

!"# !!!"#

!"#$

(C.4)

!

101

Uncertainty of Pressure and Flow Results
The uncertainties of mean pressure and mean flow results can be broken into
systematic and random errors. Systematic error includes instrument uncertainty, zeropoint error, and DAQ uncertainty. Instrument uncertainty is taken as 0.5% of the reading.
Zero-point error is the difference between the true zero value and the absolute value of
the minimum value achieved during zero-ing the equipment during calibration. Previous
work [28] from this group found the DAQ uncertainty to be ±0.003 Lpm for flow and
±0.004 mmHg for pressure. Random uncertainty is the standard error which is found
using Equation C.5.
𝑆! = 𝑆! / 𝑁

(C.5)

In Equation C.5, the term 𝑆! is the standard deviation and N is the number of mean
values (or number of cardiac cycles the data was averaged over). The results for this
thesis were averaged over N=10 cardiac cycles. The total uncertainty of the mean
variable is then found using Equation C.6 where M stands for the total number of
uncertainty terms (ui).

𝑢! =

!
!
!!! 𝑢!

(C.6)

Examples of pressure and two different flow uncertainty calculations are seen in
Table C.1. The smaller 15mm circumference flow probe used with the coronary flow
measurements resulted in less uncertainty compared to the larger 30mm circumference
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flow probe used for all other flow measurements. This was due to the smaller values of
zero-point error, instrument uncertainty, and random uncertainty.
Table C.1 Example uncertainties for flow and pressure measurements. Flow uncertainty [Lpm],
Pressure uncertainty [mmHg]

0.0090

ZeroPoint
Error
0.0035

Data
Acquisition
Uncertainty
0.003

0.0545

0.0003

0.0004

58.4491

0.2922

0.01

Name

Mean
Result

Instrument
Uncertainty

QAO

1.7934

QCOR
PAO

Random
Uncertainty

Total
Uncertainty

Relative
Value

0.0357

0.037

2%

0.003

0.000641

0.003

6%

0.004

0.04

0.30

1%

Uncertainty of Resistance and Compliance Results
The uncertainties of compliance and resistance results are found using the uncertainty
propagation methods as described by Figliola and Beasley [46]. The propagation of
uncertainty is found using Equation C.7.
!"
!
!!!(!!

𝑢! =

!

𝑢!! )!

!/!

(C.7)

In Equation C.7, uK is the uncertainty of the result, such as resistance or compliance.
!"

The term !! is the sensitivity index of each variable, 𝑥! , and 𝑢!! is the uncertainty of the
!

variable. For resistance and compliances, such variables were pressure, flow, and air
volume.
Resistance is calculated using Equation C.8 and the resulting uncertainty in resistance
(uR) is calculated using Equation C.9.
𝑅=

!! !!!

(C.8)

!
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!

!

𝑢! = (! 𝑢!! )! + (! 𝑢!! )! + (
!

!

!! !!!
!!

𝑢! )!

!/!

(C.9)

In Equations C.8-C.9, Pu and Pd are the upstream and downstream pressures,
respectively. The upstream and downstream pressures were measured independently and,
therefore, had no correlation between their uncertainties.
The compliance (C) and uncertainty in compliance (uC) are calculated using
Equations C.10 and C.11.
𝐶=!

!

(C.10)

!"#

𝑢! = (!

!!
!"#

!
! 𝑢! ) + (!

!
!"#

𝑢! )!

!/!

(C.11)

In Equation C.10 and C.11, V is the volume of trapped air in the compliance air
chamber, Pabs is the mean absolute pressure measured at the compliance air chamber. A
relative value of 1% was used for uncertainty in the volume of trapped air (uv) such that
100mL of trapped air correlated to 1mL of uncertainty. Pressure uncertainty (up) was
calculated using Equation C.6. Examples of resistance and compliance uncertainties are
seen in Tables C.2 and C.3, respectively.
Table C.2 Example uncertainty for resistance (uR) [mmHg/Lpm] [WU].
Resistance
UBSVR

PU [mmHg]
58.6

𝑢!! [mmHg]
0.3

PD [mmHg]
6.02

𝑢!! [mmHg]
0.06

𝑢! [Lpm]

Q [Lpm]
1.27

0.01

Table C.3 Example uncertainty for compliance (uC) [mL/mmHg].
Compliance
Cprox

Pabs [mmHg]
820.4

𝑢! [mmHg]
0.3
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V [mL]
77

𝑢! [mL]
0.77

𝑢!
0.006

𝑢!
5

APPENDIX D: RESULTS
Table D.1 Mean flow, mean pressure, resistance, and compliance results for the verification study.
MCS values = mean ± uncertainty
Flow [Lpm]
Cardiac Output (QAO)
Upper Body (QUB)
Lower Body (QLB)
Pulmonary (QmBTS)
Coronary (QCOR)
Pressure [mm Hg]
Ascending Aorta (PAO)
Pulmonary (PPul)
Lower Body (PLB)
Innominate (Pinom)
LSA (PLSA)
LCA (PLCA)
Coronary CA1 (PCA1)
Coronary CA2 (PCA2)
Coronary CB (PCB)
P atrium
Resistance [WU]
Upper Body (UBSVR)
Lower Body (LBSVR)
mBTS (RmBTS )
Pulmonary (Rpul)
Total Coronary (RTC)
Coronary Artery (RCOR)
Coronary CA1 (RCA1)
Coronary CA2 (RCA2)
Coronary CB (RCB)
Compliance [mL/mmHg]
CProx
CPul
CLB
CInom
CLCA
CLSA
CCA1
CCA2

Analytical
1.82
0.38
0.4
0.98
0.056
Analytical
60.11
11.06
56.71
51.21
55.91
55.91
53.61
43.71
33.8
4.1
Analytical
148
139
50
7
1000
116
177
177
530
Analytical
0.095
0.3877
0.0779
0.0888
0.0444
0.0444
0.000194351
0.000518269
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MCS
1.82 ± 0.01
0.38 ± 0.01
0.40 ± 0.01
0.98 ± 0.01
0.056 ± 0.002
MCS
60.37 ± 0.30
11.05 ± 0.06
57.56 ± 0.29
52.34 ± 0.28
49.68 ± 0.28
49.90 ± 0.26
57.51 ± 0.28
43.89 ± 0.22
33.61 ± 0.18
4.1 ± 0.34
MCS
150 ± 4
140 ± 3
50 ± 1
7 ± 0.1
1005 ± 35
51 ± 2
243 ± 9
184 ± 7
527 ± 18
MCS
0.094 ± 0.006
0.374 ± 0.14
0.057 ± 0.004
0.103 ± 0.009
0.052 ± 0.005
0.052 ± 0.005
0.00024 ± 0.00012
0.00050 ± 0.00013

Table D.2 Mean flow, mean pressure, resistance, and compliance results for the coronary verification
study. MCS values = mean ± uncertainty
Flow [Lpm]

Analytical

MCS

Cardiac Output (QAO)

1.82

1.81 ± 0.01

Upper Body (QUB)

0.37

0.37 ± 0.01

Lower Body (QLB)

0.4

0.40 ± 0.01

Pulmonary (QmBTS)

0.98

0.98 ± 0.01

Coronary Artery (QCOR)

0.056

0.057 ± 0.002

Coronary Vein (QCV)

0.056

0.056 ± 0.005

Coronary Artery (QCOR + Rcor)

0.05

0.049 ± 0.002

Coronary Vein (QCV + Rcor)

0.05

0.047 ± 0.005

Coronary Artery (QCOR ++ Rcor)

0.036

0.035 ± 0.002

Coronary Vein (QCV ++ Rcor)

0.036

0.032 ± 0.004

Analytical

MCS

Ascending Aorta (PAO)

60.11

60.65 ± 0.43

Coronary CA1 (PCA1)

53.63

54.15 ± 0.79

Coronary CA2 (PCA2)

43.72

43.94 ± 0.39

Coronary CB (PCB)

33.82

33.53 ± 0.55

Resistance [WU]

Analytical

MCS

Total Coronary (RTC)

1000

993 ± 34

Coronary Artery (RCOR)

116

111 ± 2

Coronary CA1 (RCA1)

177

180 ± 7

Coronary CA2 (RCA2)

177

183 ± 7

Coronary CB (RCB)

530

518 ± 18

RCOR + Rcor

232

232 ± 2

RCOR + + Rcor

691

691 ± 5

Analytical

MCS

CCA1

0.000194351

0.00025 ± 0.00012

CCA2

0.000518269

0.00050 ± 0.00013

Pressure [mm Hg]

Compliance [mL/mmHg]
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Table D.3 Mean flow, mean pressure, resistance, and compliance results for the MUSC2 validation
study. MCS values = mean ± uncertainty
Flow [Lpm]

Clinical

MCS

Cardiac Output (QAO)

1.26

1.25 ± 0.01

Upper Body (QUB)

0.31

0.30 ± 0.01

Lower Body (QLB)

0.32

0.31 ± 0.01

Pulmonary (QmBTS)

0.58

0.58 ± 0.01

Coronary (QCOR)

0.05

0.049 ± 0.002

Clinical

MCS

58.76

58.99 ± 0.30

12

12.61 ± 0.06

Coronary CA1 (PCA1)

52.33

51.86 ± 0.26

Coronary CA2 (PCA2)

42.55

41.86 ± 0.21

Coronary CB (PCB)

32.77

30.39 ± 0.15

Clinical

MCS

Upper Body (UBSVR)

170

175 ± 6

Lower Body (LBSVR)

166

169 ± 6

mBTS (RmBTS )

80

79 ± 1

Pulmonary (Rpul)

10

11 ± 0.2

Total Coronary (RTC)

1055

1073 ± 44

Coronary Artery (RCOR)

129

144 ± 6

Coronary CA1 (RCA1)

196

203 ± 8

Coronary CA2 (RCA2)

196

232 ± 10

Coronary CB (RCB)

535

494 ± 20

Analytical

MCS

CProx

N/A

0.082 ± .006

CPul

N/A

0.29 ± .08

CLB

N/A

0.081± .009

CInom

N/A

0.117± .011

CLCA

N/A

0.115 ± .008

CCA1

0.00017

0.00025 ± 0.00012

CCA2

0.00046

0.00050 ± 0.00013

Pressure [mm Hg]
Ascending Aorta (PAO)
Pulmonary (PPul)

Resistance [WU]

Compliance [mL/mmHg]
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Table D.4 Mean flow, mean pressure, resistance, and compliance results for the MUSC2 mBTSparametric study using the 3.5mm mBTS. MCS values = mean ± uncertainty
Flow [Lpm]
Cardiac Output (QAO)
Upper Body (QUB)
Lower Body (QLB)
Pulmonary (QmBTS)
Coronary (QCOR)
Pressure [mm Hg]
Ascending Aorta (PAO)
Pulmonary (PPul)
Atrium (PAtr)
Coronary CA1 (PCA1)
Coronary CA2 (PCA2)
Coronary CB (PCB)
Resistance [WU]
Upper Body (UBSVR)
Lower Body (LBSVR)
mBTS (RmBTS )
Pulmonary (Rpul)
Total Coronary (RTC)
Coronary Artery (RCOR)
Coronary CA1 (RCA1)
Coronary CA2 (RCA2)
Coronary CB (RCB)
Compliance [mL/mmHg]
CProx
CPul
CLB
CInom
CLCA
CCA1
CCA2

Clinical
1.26
0.31
0.32
0.58
0.05
Clinical
58.76
12
6
52.33
42.55
32.77
Clinical
170.2
165.9
80.1
10
1055
129
196
196
535
Analytical
N/A
N/A
N/A
N/A
N/A
0.00017
0.00046
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MCS
1.27 ± 0.01
0.31 ± 0.01
0.32 ± 0.01
0.58 ± 0.01
0.051 ± 0.002
MCS
58.63 ± 0.30
11.96 ± 0.06
6.02 ± 0.06
52.83 ± 0.26
43.04 ± 0.21
32.28 ± 0.15
MCS
169 ± 5
164 ± 5
80 ± 1
10 ± 0.2
1055 ± 41
114 ± 4
193 ± 8
212 ± 8
517 ± 20
MCS
0.082 ± .006
0.29 ± .08
0.081± .009
0.117± .011
0.115 ± .008
0.00025 ± 0.00012
0.00050 ± 0.00013

Table D.5 Waveform comparison results for all studies: Root-mean-square (RMS), normalized RMS
(NRMS) by mean and range, and coefficient of determination (R2).
NRMS by range
(𝜎)

R2

8.6%

8.6%

0.92

52.4%

14.7%

0.83

13.2%

41.0%

0.83

RMS

NRMS by mean
(𝜔)

NRMS by range
(𝜎)

R2

PAO

4.957

8.2%

10.2%

0.94

QCOR

0.025

44.1%

12.6%

0.87

QCV

0.033

58.8%

15.8%

0.85

QCOR + R

0.022

44.6%

13.3%

0.87

QCV + R

0.034

71.5%

16.0%

0.88

QCOR ++ R

0.011

32.0%

11.0%

0.91

QCV ++ R

0.030

94.5%

14.2%

0.89

MUSC2 Validation
Study

RMS

NRMS by mean
(𝜔)

NRMS by range
(𝜎)

R2

PAO

3.98

6.7%

6.0%

0.97

QmBTS

0.07

11.3%

13.5%

0.97

QAO

0.48

38.3%

9.9%

0.92

3.5 mBTS Parametric
Study Validation

RMS

NRMS by mean
(𝜔)

NRMS by range
(𝜎)

R2

PAO

7.02

12.0%

11.7%

0.90

QmBTS

0.05

7.8%

9.7%

0.98

QAO

0.41

32.7%

7.3%

0.97

Verification Study

RMS

PAO

5.21

QCOR

0.03

QmBTS

0.13

Coronary
Verification Study

NRMS by mean
(𝜔)
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